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DEVELOPMENT OF NEUROTENSIN-BASED
RADIOPHARMACEUTICALS FOR
NEUROTENSIN-RECEPTOR-1-POSITIVE TUMORS TARGETING
Yinnong Jia, Ph.D.
University of Nebraska Medical Center, 2017
Supervisor: Jered C. Garrison, Ph.D.
The neurotensin receptor 1 (NTR1) is overexpressed in many cancers, due to
its role as a growth pathway. These NTR1-positive cancers include pancreatic, colon,
prostate and breast cancers. In the radiopharmaceutical field, the overexpression of
NTR1 in cancer has prompted the development of NTR1-targeted diagnostics and
therapeutics. The neurotensin (NT) peptide exhibits low nanomolar affinity for NTR1
and has been the paradigm for NTR1-targeted agents. Since the 1980’s, radiolabeled
NT analogs have been developed and evaluated for targeting NTR1-positive cancers.
Since native NT is rapidly degraded in vivo by a variety of peptidases, a tremendous
amount of effort has been put forth to design stabilized NT analogs with increased in
vivo efficacy. To further enhance NTR1-targeted agents for diagnosis and therapy, our
work has focused on strategies to increase the binding affinity, stability and optimize
the pharmacokinetic profile of NTR1-targeted radiopharmaceuticals. In this
dissertation, our work includes: 1) the investigation of the structure-activity
relationship of the spacer groups in the NTR1-targeted agent design; 2) the evaluation
of the effect charge distribution has on NTR1 binding and the biodistribution profile
and 3) the utilization of peptidase inhibitors to extend the activity of NTR1-targeted
agents.

iv
It is well known that 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid
(DOTA), and other radiometal chelators, can negatively impact the receptor binding
of targeted peptides. Utilizing DOTA and a known metabolically stabilized
NTR1-targeted peptide ([(N-α-Me)Arg8,Dmt11,Tle12]NT(6-13)), we evaluated a series
of spacer groups to examine what steric impact, if any, DOTA had on NTR1-targeted
peptides. We observed that the binding affinity was negatively affected by the direct
conjugation (i.e., absence of spacer) with DOTA. However, the optimal binding
activity can be restored with the inclusion of β-Ala or longer spacer groups. Our
following studies investigated the impact the Lys 6 charge had on NTR1 binding and
the overall biodistribution profile. It was observed that translation of this amino acid
further away from the peptide influenced the receptor binding, internalization and
kidney retention profile of the NTR1-targeted peptide. Lastly, we examined if
peptidase inhibitors, such as phosphoramidon (PA), would improve the targeting
efficacy of NTR1-targeted agents. We observed that PA limited the degradation of the
peptide and resulted in an increased NTR1-positive tumor uptake. Based on these
findings, we increased our understanding of the structure-activity relationships and in
vivo degradation of NTR1-targeted agents. Utilizing this knowledge, we plan on
optimizing the design of future NTR1-targeted agents for diagnostic imaging and
radiotherapy.
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Chapter 1:
INTRODUCTION

2

1.1

Peptide-based radiopharmaceuticals
Small molecules bearing radionuclides for targeting cancers have been of

interest for diagnostic as well as therapeutic purposes [1–5]. One successful example of
small molecule diagnostic agents is 18F-FDG (18F-fluorodeoxyglucose), which exhibits
high uptake in many cancers due to the reliance of cancers on glucose metabolism [6].
In order for a radiopharmaceutical to be considered successful, it must accumulate at a
high level within the target tissues, as well as clear from the blood and other non-target
organs in the time frame that is compatible with the half-life (t1/2) of the radionuclide
[7–9]. One class of small molecules being actively investigated are regulatory peptides,
such as the somatostatin, bombesin, cholecystokinin and neurotensin (NT), due to the
favorable

pharmacokinetic

properties

of

these

molecules

[9–14].

Most

receptor-targeted peptides that have been investigated for diagnosis and therapy are
based on endogenous bioactive molecules [8,9,12,15–17]. Because of this and their
relatively small size, receptor-targeted peptides are generally not antigenic [18].
Advantages of peptides over monoclonal antibodies, another class of molecules
employed for tumor scintigraphy and treatment, include ease of synthesis and
modification, ability to withstand harsher chemical conditions (i.e., acids and heat), and
the significantly faster plasma clearance [19].
In the early 1990s, the first clinically successful receptor-targeted peptide was
obtained with [111In-DTPA0]octreotide (Octreoscan™), a somatostatin peptide binding
with high affinity to somatostatin receptors found at high densities in several
neuroendocrine tumors [20]. To date, [111In-DTPA0]octreotide has been clinically
utilized for the detection of carcinoids and pancreatic neuroendocrine tumors [5,20–23].

3
Additionally, 90Y- and

177

Lu-labeled somatostatin analogues have been developed for

peptide receptor radionuclide therapy (PPRT) to treat gastroenteropancreatic
neuroendocrine tumors [7,10,21,22]. To improve the targeting capabilities of
radiolabeled pharmacophores to somatostatin receptors, the field has evolved to the
examination of radiolabeled somatostatin receptor antagonists that have shown
superior pharmacokinetics in pilot studies [24,25]. The successes related to
somatostatin receptor targeting has propelled the field forward into the development of
other applicable regulatory peptide derivatives for tumor diagnosis and therapy
[16,20,26–30]. Such peptides or peptide analogues investigated include, but are not
limited to, bombesin [28], substance P [29], cholecystokinin [26,27] and neurotensin
[31,32]. A representative list of receptor-targeted peptides under development is given
in Table 1.1.
In general, the components of receptor-targeted peptides include a peptide
targeting vector, a chelator, a spacer group and a radiometal. The peptide targeting
vector is responsible for obtaining target selectivity. The ideal peptide targeting vector
is one with high in vivo affinity and stability to maximize target accumulation.
Chelators, typically referred to as bifunctional chelating agents due to its metal binding
and requisite conjugation chemistries, are utilized to stabilize radiometals and
minimize the possibility of in vivo radiometal release [33–35]. For some
receptor-targeted peptides, spacer groups are utilized to minimize steric inhibition of
the pharmacophore by other structural components, such as the chelation system
[36,37]. In addition, spacer groups can be a convenient handle to modify the
hydrophilicity of the receptor-targeted agent without making structural changes to the
targeting vector [36]. Lastly, the selection of the radiometal is based on the desired
application, diagnostic imaging or radiotherapeutic treatment.
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Table 1.1. Selected Peptides and Receptors in Tumorsa [19].
Peptide

Receptor types

Tumor expression

Somatostatin

sst1, sst2, sst3,

Neuroendocrine tumors (gastroenteropancreatic

sst4, sst5

tumors), lymphoma, paraganglioma, carcinoids,
breast, brain, renal, small cell lung cancer,
medullary thyroid cancer

Bombesin/

BB1, BB2, BB3, Prostate, breast, pancreas, gastric, colorectal,

GRP

BB4

small cell lung cancer

VIP

VPAC1,

Adenocarcinomas of breast, prostate, stomach

VPAC2

and liver; neuroendocrine tumors

α-MSH

MC1-5R

Melanomas

CCK/gastrin

CCK1, CCK2

Medullary thyroid cancer, small cell lung cancer,
gastrointestinal stromal tumor, stromal ovarian
cancer, astrocytomas

Neurotensin

NTR1, NTR2,

Small cell lung cancer, colon, exocrine ductal

NTR3

pancreatic cancer, Ewing sarcoma, meningioma,
astrocytoma, breast, prostate cancer

LHRH

LHRH-R

Prostate, breast cancer

Substance P

NK1, NK2,

Glial tumors (glioblastoma, medullary thyroid

NK3

cancer), pancreas, breast, small cell lung cancer

GLP-1

Insulinomas, gastrinomas, pheochromocytomas,

Exendin

paragangliomas and medullary thyroid
carcinomas
RGD
a

αvβ3-integrin

Glioma, breast, prostate cancer

GRP, gastrin-releasing peptide; VIP, vasoactive intestinal peptide; α-MSH,
α-melanocyte-stimulating hormone; CCK, cholecystokinin; LHRH, luteinizing
hormone-releasing hormone; GLP, glucagon-like peptide; RGD, Arg-Gly-Asp
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The types of radioisotope decays include γ, β+, β-, α, and Auger emissions [7].
For diagnostic imaging, radiometals that emit γ photons and β+ particles are utilized for
use with single photon emission computed tomography (SPECT) or positron emission
tomography (PET), respectively. The commonly used radioisotopes and chelators of
NT-based radiopharmaceuticals are listed in Table 1.2. To date, 68Ga, 64Cu and 18F have
been used for the development of NT-based PET radiopharmaceuticals [38–40]; 99mTc-,
111

In and

177

Lu have been investigated for SPECT imaging agent development

[31,41–46]. In our studies, we utilized

177

Lu (t1/2= 6.67 days) which is a theranostic

radioisotope due to its dual γ photons and β- emission profile [47,48].

177

Lu emits γ

photons (113 and 210 keV) which have high enough energies to penetrate tissues and
provide a signal that is compatible with SPECT detection. In addition,

177

Lu emits β-

particles, a form of ionizing radiation that damages cellular DNA thereby killing
affected

cells

[48].

To

stably

chelate

177

Lu,

we

selected

the

1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) chelator, a common
chelation system utilized in clinical medicine . DOTA has been shown to stably chelate
177

Lu in vivo and has been a mainstay of radiopharmaceutical agent design [48].
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Table 1.2. Characteristics of Radioisotopes and Chelators used for NT-based peptides.
Radioisotopes

Half-life

Chelators

Application

Technetium-99m

6.0 h

(NαHis)Ac,

Diagnosis (SPECT)

(99mTc)

MAG3, HYNIC

Fluorine-18 (18F)

1.8 h

SFB

Diagnosis (PET)

Gallium-68 (68Ga)

1.1 h

NOTA, DOTA

Diagnosis (PET)

Copper-64 (64Cu)

12.7 h

DOTA

Diagnosis (PET)

Indium-111 (111In)

67.2 h

DTPA, DOTA

Diagnosis (γ imager)

Lutetium-177 (177Lu)

160.8 h

DOTA

Diagnosis (SPECT)

Rhenium-188 (188Re)

17.0 h

(NαHis)Ac

Therapy

Thallium-201 (201Ti)

73.1 h

DTPA

Diagnosis (SPECT)
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1.2

Neurotensin receptors and cancers
Neurotensin (NT) receptors have been found to be overexpressed as a growth

pathway for the proliferation, survival, migration, invasion and neoangiogenesis of
numerous cancers [49]. Reubi and coworkers [50] have observed overexpression of NT
receptors in clinically relevant human tumors, such as Ewing’s sarcoma (65%),
meningioma (52%), astrocytoma (43%), medulloblastoma (38%), medullary thyroid
carcinoma (29%) and small cell lung cancer (25%). In addition to the above cancers,
the occurrence of NT receptors has been reported in high abundance in ductal
pancreatic adenocarcinoma (75%) [51,52], invasive ductal breast cancers (91%) [53,54]
and malignant mesothelioma (90%) [55]. To date, the increased expression of NT
receptors has been shown to contribute to the tumor progression in non-small cell lung
cancer [56], colon adenocarcinoma [57], head and neck squamous cell carcinoma [58]
and prostate cancer [59]. The high occurrence of NT receptors in such prevalent
cancers has led to an increased interest in the development of imaging moieties for
targeting NT receptors in the last three decades. Despite the ongoing research
concerning radiopharmaceuticals for targeting NT receptors, to date only two clinical
studies have been performed [41,60], both lacking the desired pharmacokinetic
performances required for a successful radiopharmaceutical agent.
Currently, there are four NT receptors that have been identified. Two of the
identified receptors, NTR1 and NTR2, have been found in human and belong to the
G-protein coupled receptor family, demarked by the seven putative transmembrane
domains of this class [61,62]. NTR3, also found in human, belongs to sortilin family of
proteins as an intracellular sorting protein and is composed of a single transmembrane
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domain [62–65]. Recently, a fourth NT receptor (NTR4) belonging to the G-protein
coupled receptor family was identified in bullfrogs [66].
Of most interest, with respect to cancer imaging and therapy, is the NTR1
(424-amino-acid protein in rat and 418-amino-acid protein in human) which mediates
most of the NT biological effects and is found overexpressed in various cancers
[61,67,68]. The high expression of NTR1 in cancerous tissues is linked to signaling
pathways in which NTR1 facilitates several transforming functions such as cell
proliferation, migration, tumor angiogenesis, and metastasis [49,69,70]. The high
NTR1 expression in numerous cancers, the minimal or lack of expression in normal
surrounding tissues, and the fact that NT exhibits high affinity (Kd = 0.2 nM) for the
NTR1 [71,72] has prompted the development NTR1-targeted radiopharmaceuticals
[26,50–52,73,74].

1.3

NT and NTR1
Initially isolated from the bovine hypothalamus [75] in 1973 and later obtained

from the bovine intestines [76] in 1976 by Carraway and Leeman, NT is a
13-amino-acid, linear peptide with the sequence of Glu-Leu-Tyr-Glu-Asn-Lys-ProArg-Arg-Pro-Tyr-Ile-Leu. It has been shown to bind to NTR1 receptors with high
nanomolar affinity. Functioning as both a neuromodulator and local hormone in
mammals, NT is found in the central nervous system and peripheral tissues (mainly the
gastrointestinal tract) [77–79]. Structural information concerning the molecular
binding of the ligand NT to NTR1 has recently been published and has increased our
understanding of the ligand-receptor interactions [62,72,80,81]. The binding
interactions of NT to NTR1 were first investigated by Bernassau, Kitabgi, and
Labbé-Jullié [72] utilizing alanine scanning and receptor mutagenesis methods, but
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some details concerning the receptor/ligand interaction remained unclear. It was not
until White and coworkers were able to obtain the crystal structure of NTR1, from
Rattus norvegicus, binding to NT(8-13) that a detailed analysis of the ligand-receptor
interactions was possible [62]. In this study, conformation thermostabilization of NTR1
(NTR1-GW5-T4L) allowed the crystal structure of the active-like state to be obtained
at 2.8 Å resolution (Figure 1.1). The structure of the NTR1 binding pocket was found to
be composed of three extracellular loops (ECL1-ECL3) and six transmembrane helices
(TM2-TM7). Of the findings, charge interactions were observed between the
positive-charged arginine side chains of NT(8-13) and the electronegative rim of the
binding site. The formation of a salt bridge between the C-terminus of NT(8-13) and
R327 of the receptor is probable along with van der Waals interactions and three
hydrogen bonds between the side chains of the central regions of NT(8-13) and the
receptor [62]. As a consequence, these interactions result in directing the N-terminus
end out of the binding pocket (Figure 1.2). These observations confirm previous studies
that have shown that only the NT(8-13), C-terminus sequence (Arg-Arg-Pro-Tyr-IleLeu-OH) is needed for high binding affinity to the NTR1 [67]. Due to this, the majority
of NTR1-targeted agents have utilized truncated NT sequence such as NT(8-13) and
NT(6-13) [44,82–84].
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Figure 1.1. Overview of the NTR1 structure bound to the peptide agonist NT8–13.
(a) side view (b) extracellular view and (c) intracellular view of the NTR1.
Adapted with permission from Nature Publishing Group [62]
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Figure 1.2. The extracellular views of NTR1 binding pocket with NT(8–13). (a) the
ligand-binding pocket (b) The interaction between NTR1 (green residues
with grey labels) and NT(8-13) (grey residues with bold black labels).
Dashed lines: hydrogen bonds and salt bridges. (c) The charge
complementarity between NT(8-13) and its binding pocket (red, negative;
blue, positive). Adapted with permission from Nature Publishing Group
[62]
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1.4

The optimization of NT-based radiopharmaceuticals
As with all targeted radiopharmaceuticals, the development of NT-based agents

for cancer diagnosis and therapy has focused on increasing NTR1-positive tumor
uptake, while minimizing non-target retention. In order to successfully translate the
NT-based radiopharmaceuticals into the clinic, research have focused on increasing the
stability and NTR1-affinity of agents under development.
1.4.1 Degradation of NT
The lack of plasma stability due to rapid degradation has been a major hurdle to
overcome in the design of imaging and therapeutic agents based on NT. The rapid
degradation of these peptides results in metabolites with no NTR1-affinity and,
ultimately, leads to poor in vivo tumor uptake. For example, in a recent clinical study,
the low tumor uptake of

99m

Tc-Demotensin VI (N4-β-Ala-Arg-Dab-Pro-Tyr-Tle-

Leu-OH), a NTR1-targeted agent, was attributed to the rapid degradation of this
NT-based radiopeptide in vivo [41]. Findings such as this have given the impetus for the
development of “stabilized” NT analogs with replacements using natural and unnatural
amino acids. However, even with these replacements, we and others have observed that
the in vivo degradation of “stabilized” NTR1-targeted agents, while inhibited, still
occurs [85].
To date, the major endogenous peptidases responsible for cleavages of NT have
been revealed [86–88]. These four peptidases responsible for the NT degradation are
zinc-dependent peptidase members of the metalloendopeptidase family [24,68,69]: (1)
The neutral endopeptidase 24.11 (EC 3.4.24.11, neprilysin, NEP); (2) angiotensinconverting enzyme (EC 3.4.15.1， ACE); (3) metalloendopeptidase 24.15 (EC
3.4.24.15, thimet oligopeptidase, TOP); and (4) metalloendopeptidase 24.16 (EC
3.4.24.16, neurolysin). With respect to the NT(8-13) truncated sequence, TOP is
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known to hydrolyze the Arg8-Arg9 bond, neurolysin cleaves the Pro10-Tyr11 site, ACE
hydrolyses the Tyr11-Ile12 amide bond and NEP can degrade both the Pro10-Tyr11 and
Tyr11-Ile12 sites (Figure 1.3). To better understand the process and location of
degradation, the distribution of these four peptidases have been reported [89]. NEP is a
cell membrane-bound protein that is present on the vascular wall and is also distributed
in tissues such as the kidney, intestine, lung and brain [89]. TOP is present in both
soluble and membrane-bound forms that are widely distributed in tissues, such as the
liver, brain, lung and kidneys [90,91]. Neurolysin and ACE are found in soluble forms
located predominately in the cytoplasm of the cells. Neurolysin is distributed mostly in
the kidney, brain and liver, while ACE is distributed in the lung, kidney, intestine and
brain [89].
1.4.2 Modification of NT-based radiopharmaceuticals to increase stability
To radiolabel and stabilize NT from degradation, while retaining the high
binding affinity of the targeting vector, many groups have focused on modifying the
essential amino acid sequence of NT(8-13) [31,32,43,44,92]. The modifications that
have been made to increase the metabolic stability of NT-based agents include
introducing pseudopeptide bonds between amino acids, substituting selected amino
acids with unnatural amino acids and/or N-methylation [31,32,43,44,92,93]. Below, we
discussed how investigators have utilized these different modifications to stabilize the
NT-based radiopharmaceuticals and the resulting biological effect caused by these
alterations.
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Figure 1.3. Peptide bond cleavage of NT.
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1.4.2.1 Modifications at Arg8-Arg9
The most common modifications to stabilize NTR1-targeted agents were made
between amino acids Arg8-Arg9, due to the susceptibility of this peptide bond to
proteolytic cleavage by TOP. Utilizing a DTPA-NT(8-13) analogue, Tourwé and
coworkers modified the Arg8 by replacing it with a Lys. This modification was found to
increase metabolically stability while still retaining high NTR1-affinity [94]. In
addition, the amide bond (CO-NH) between Arg8-Arg9 was replaced with a
pseudopeptide isosteric bond Ψ(CH2-NH) to make it even more resistant to enzymatic
cleavage. With these modification, the plasma stability increased from 10 min for
111

In-DTPA-NT(8-13) to 275 min for 111In-DTPA-Lys8-Ψ(CH2-NH)-Arg9-NT(10-13),

demonstrating that these modifications substantially increased in vivo stability [94]. In
regards to NTR1-binding affinity, these modifications were found to be well tolerated
and still resulted in low nanomolar binding affinity.
The investigation of Mindt’s group demonstrated the same conclusions that the
modifications to Arg8-Arg9 could be made to stabilize the peptide without significantly
decreasing binding affinity. They replaced the amide bond with a triazole ring between
Arg8-Arg9 to evaluate the structure-activity relationship. The percentage of intact
peptide increased from 0.9 ± 0.3 % after 4 h (t1/2= 39.4 min) to 6.5 ± 4.6% after 4 h
(t1/2= 64.9 min) in blood serum [95].
Another approach to stabilize the Arg8-Arg9 site has been to N-methylate the
Arg8. Using DTPA-substituted NT analogues, Tourwé and coworkers found that
N-methylation of the Arg8 did not influence the binding affinity significantly. The
representative NT-based peptides, NT-20.1 (truncated structure), NT-20.2 (with one
modification) and NT-20.3 (with two modifications) have been shown in Table 1.3. As
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shown in the Table 1.4, the in vitro and in vivo stability has been improved more
significantly in NT-20.3 with both N-methylation at Arg8 and the Tle12 modifications
compared to NT-20.2 with only Tle12 modification [84]. The decreased binding affinity
in NT-20.2 (41.2 ± 6.2 nM) has been restored with the dual-modifications in the
NT-20.3 (15.9 ± 1.7 nM), as compared with the NT-20.1 (6.73 ± 0.31 nM). The
internalization rate remained similar to an unmodified NT analog control, namely
[Lys6(DTPA(In))]-N [84]. Most importantly, the DTPA-NT-20.3 exhibited the highest
tumor uptake at 1 h (~3 fold higher than [Lys6(DTPA(In))]-NT, ~ 7 fold higher than
DTPA-NT-20.1 and ~ 3.5 fold higher than DTPA-NT-20.2). Additionally, due to the
higher tumor uptake, DTPA-NT-20.3 demonstrated the highest tumor to normal tissues
ratios[84]. The improved stability and, as a consequence, the increased tumor uptake of
DTPA-NT-20.3 demonstrates that this modification can substantially increase the
diagnostic and therapeutic potential of NTR1-targeted agents.
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Table 1.3. Selected NT Analogs with Arg8-Arg9 Modifications [44,84].
Peptides

Sequences

Lys6(DTPA)-NT

pGlu-Leu-Tyr-Glu-Asn-Lys(DTPA)-Pro-Arg-Arg-Pro-Tyr-IleLeu-OH

DTPA-NT-20.1

Ac-Lys (DTPA)-Pro-Arg-Arg-Pro-Tyr-Ile-Leu-OH

DTPA-NT-20.2

Ac-Lys (DTPA)-Pro-Arg-Arg-Pro-Tyr-Tle-Leu-OH

DTPA-NT-20.3

Ac-Lys (DTPA)-Pro-(NMe)Arg-Arg-Pro-Tyr-Tle-Leu-OH

DOTA-NT-20.3

Ac-Lys (DOTA)-Pro-(NMe)Arg-Arg-Pro-Tyr-Tle-Leu-OH

DOTA-NT-20.4

Ac-Lys (DOTA)-Pro-Arg-(NMe)Arg-Pro-Tyr-Tle-Leu-OH

18

Table 1.4. The Binding Affinity, Stability and Tumor Uptake of the NT-Analogs with
Modifications [44,84].
Peptides

IC50 (nM)

Lys6(DTPA)-NT 17.0 ± 4.0

In vitro
stabilitya
(t1/2)
25.0 ± 2.0

In vivo
stabilityb
(15 min)
4.0

Tumor
uptakec
at 1 h
1.0 ± 0.3

Tumor
uptake
at 3 h
0.7 ± 0.2

DTPA-NT-20.1

6.7 ± 0.3

0.4 ± 0.02

0.8

0.5 ± 0.1

0.5 ± 0.1

DTPA-NT-20.2

41.2 ± 6.2

4.4 ± 0.6

10.0

0.9 ± 0.3

0.5 ± 0.1

DTPA-NT-20.3

15.9 ± 1.7

257.0 ± 71.0

26.5

3.3 ± 0.2

2.4 ± 0.2

DOTA-NT-20.3

15.0 ± 1.0

ND

22.0 ± 1.0

4.7 ± 0.8

2.5 ± 0.2

DOTA NT-20.4

190.0 ± 20.0

ND

16.0 ± 2.0

0.8 ± 0.1

0.5 ± 0.1

a

In vitro stability is expressed as the half-life in human serum at 37 °C

b

The percentage of intact peptide in plasma has been evaluated at 15 min after
injection.

c

The tumor uptake was depicted as the %ID/g.
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In contrast to modification at Arg8, the NT-20.4 utilizes the N-methylation of
Arg9. This modification was found to dramatically decrease the binding affinity of the
resulting analog. The IC50 value of In-DOTA-NT-20.4 increased dramatically to
190 ± 20 nM from 15 ± 1 nM for In-DOTA-NT-20.3 [44]. With the decreased binding
affinity, the NTR1-positive, tumor uptake of In-DOTA-NT-20.4 was only
0.8 ± 0.1 % ID/g. In another study, the concurrent replacement of Arg8 by Gly(PipAm)
and Arg9 by Gly(Pip) (as shown in Figure 1.4) resulted in a substantial loss of affinity
relative to Arg8 modification alone [83]. Thus, during the pursuit of higher stability
NTR1-targeted agents, the effect these modifications have on binding affinity should
be carefully considered.
Based on the discussion above, the results demonstrate that modifications to
the Arg8-Arg9 site were feasible and effective in increasing in vivo stability. These
modifications led to approximately 10-20 fold increase in in vivo plasma stability
relative to the native sequence. However, modifications to the Arg8 are generally
more tolerated in terms of maintaining NTR1-binding affinity relative to Arg9.
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Figure 1.4. Structures of the amino acids utilized to modify the Arg8 and Arg9.
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1.4.2.2 Modifications at Tyr11-Ile12
Another site of the NT targeting vector that is sensitive to degradation is the
Tyr11-Ile12 position. However, unlike modifications to the Arg8-Arg9 site, modifications
to the Tyr11-Ile12 position are less tolerated and as a result the numbers of successful
modifications are fewer. The structures of the amino acids that replace the Tyr11 and
Ile12 have been listed in Figure 1.5. These modifications are believed to inhibit the
degradation of the NT based peptide by ACE, NEP and neurolysin.
For the discussion of the Tyr11-Ile12 modifications, the structures of the
NT-based examples are listed in Table 1.5. The replacement of Tyr11 by
2,6-dimethyltyrosine (Dmt) is a common modifications. Many analogs has shown that
this modification improves stability while preserving NTR1-binding affinity. For
example, NT-XIX, which includes the Dmt11 modification, has similar binding affinity,
but substantially increased stability relative to NT-XII, which lacks this modification
[43,96]. However, other attempts at modifying or substituting Tyr11 have included the
insertion of triazole rings or the replacement with mTyr [83]. These modifications have
resulted in negligible improvement to the stability of the peptide and complete or partial
loss of binding affinity [95]. Interestingly, in one instance, the replacement L-Tyr11 with
11

D-Tyr

has been shown not to impact stability or NTR1-affinity [83]. This is somewhat

unexpected since it has been shown that Tyr11 contributes (phenol group) to the binding
affinity through hydrogen bonding to hydroxyl group (Thr) in the NTR1 binding
pocket.
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Figure 1.5. The structures of Tyr, Ile and their analogs.
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Table 1.5. The NT Analogs with Modifications (the proposed alterations are in bold).
Peptides

Sequences

NT-XI

(NαHis)Ac-Lys-Ψ(CH2NH)-Arg-Pro-Tyr-Tle-Leu

NT-XIX

(NαHis)Ac-Arg-(NMe)Arg-Pro-Dmt-Tle-Leu

NT-VIII

(NαHis)Ac-(NMe)Arg-Lys-Pro-Tyr-Tle-Leu

NT-LB119

Ac-Lys (Ahx-DOTA)-Pro-(NMe)Arg-Arg-Pro-Dmt-Tle-Leu-OH
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The position of Ile12 has been shown to be one of the most, if not the most,
effective sites to increase the metabolic stability of NTR1-targeted agents [95]. For
example, the replacement of Ile12 by Tle (tert-Leu) resulted in a stability increase from
4.3% to 72% in human serum after 24 h incubation [83]. Although a significant
reduction in the cell internalization rate and binding affinity was observed with this
modification, the higher tumor uptake due to the increased stability made up for any
loss in NTR1-affinity or internalization rate [95]. Interestingly, the insertion of a
triazole at the position of Ile12, resulted in a more stable peptide, but a complete loss in
binding affinity [95].
1.4.2.3 Modifications at Leu13
The modification at Leu13 is not commonly applied to increase the stability of
NT-based radiopharmaceuticals considering that peptidase degradation at this site is
limited and there is a risk of complete loss in NTR1 binding affinity. As mentioned
previously, the crystal structure of NT(8−13) bound to NTR1 has demonstrated that the
Leu13 participates in ionic and hydrogen bonding to the residues of the receptor [62]. To
date, modifications of the Leu13 have not provide any substantial overall benefits in
terms of metabolic stability and, in some cases, have adversely affected binding to the
receptor. For example, Mindt’s group demonstrated that the insertion of triazole at the
C-terminus resulted in a total loss of binding affinity [95]. In addition, the replacement
of Leu13 by Cpa, Cha or tBuAla (Figure 1.6) decreased the binding affinity and did not
improve the stability significantly [83].
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Figure 1.6. The Cpa, Cha and tBuAla that used to modify Leu13.
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1.4.2.4 Enhancing stability using enzyme inhibitors
Rather than modifying the structure of the NT based targeting vector, which can
sometimes negatively impact affinity, the utilization of enzyme inhibitors to
temporarily protect radiopeptides from in vivo peptidase degradation was first proposed
by De Jong and colleagues [97]. Phosphoramindon (PA), the inhibitor of NEP has been
shown to dramatically increase the in vivo targeting efficacy of receptor-targeted
peptides, such as bombesin, gastrin/CCK and somatostatin analogs [97,98]. The
increased in vivo targeting is associated with a decrease in NEP metabolism resulting in
an increase in in vivo metabolic stability [97–100]. Two other NEP inhibitors,
thiorphan and its prodrug racecadotril, have also been shown to increase the in vivo
stability and tumor uptake of radiolabeled gastrin analogs (111In-DOTA-MG11);
however, the effects of these analogs are not as potent as PA [101,102]. The
co-injection of the ACE inhibitor, lisinopril showed no effect on increasing the tumor
uptake of 111In-DOTA-MG11, which indicates that ACE is not significantly involved in
the degradation of 111In-DOTA-MG11 [102].
Because NEP and ACE are both responsible for the degradation of NT, we
expect that co-formulating NEP and ACE inhibitors with NT-based peptides could be
potentially beneficial. In our approach, we investigated PA (NEP inhibitor) and IPP
(Ile-Pro-Pro, an ACE inhibitor) with NT analogs to evaluate the effect on the in vivo
tumor uptake and stability. In addition, we investigated the effect of bradykinin (a
competitive substrate for NEP, ACE and TOP) as well as a short peptide containing the
most common metabolic sites of the NT(8-13) sequence (Pro-Arg-Arg-Pro-Tyr). These
studies will be explored in Chapter 4.
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1.4.3 The utilization of spacer groups to decrease steric inhibition and modify
hydrophilic properties
The insertion of spacer groups is considered an effective method to decrease the
steric inhibition of receptor-targeted agents, thus restoring binding affinity. Common
chelators, such as DOTA and DTPA, are ideal for stabilizing radiometals, such as 177Lu,
111

In and 68Ga. However, the introduction of DOTA too close to the NT pharmacophore

can negatively impact binding affinity, particularly for those utilizing the smallest
NT(8-13) fragment as a targeting vector. This loss of affinity is attributable to the steric
bulk of the chelator. The introduction of various spacer groups in some NT analogs
have been shown to restore optimal binding affinity by increasing the distance between
the macrocyclic chelator and the targeting vector. For example, our studies have shown
that the binding affinity of a NT(6-13) derivative was restored by the insertion of
spacers groups, such as β-Ala, 5-Ava or 8-Aoc. This work will be further discussed in
Chapter 2.
In addition to reducing steric inhibition, spacer groups can also be utilized to
easily adjust the hydrophilicity of receptor-targeted peptides. Hydrophilicity is an
important factor to consider in order to achieve optimal target to non-target ratios.
Analogs that are too hydrophilic may have reduced circulation times, while analogs that
are too hydrophobic may have increased hepatobiliary clearance and poor tissue
diffusion. To quantitate the hydrophilicity of a charged species in biological milieu, the
distribution coefficient, LogD, is commonly used. The LogD values of various reported
NTR1-targeted peptides are shown in Table 1.6. For example, DOTA-Ahx-NT(8-13)
(177Lu(2)) has a LogD of -2.30, while DOTA-PEG4-NT(8-13) (177Lu-NT2) has a LogD
of -2.40, suggesting that the PEG4 is able to increase the hydrophilicity of the analog
relative the Ahx hydrocarbon.
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Table 1.6. The Selected NT Analogs and LogD Values.
Analogs

Sequences

LogD

Ref

177

Lu(2)

DOTA-Ahx-NT(8-13)

-2.30

[103]

177

Lu-NT 1

DOTA-NT(8-13)

-2.50 ± 0.30

[104]

177

Lu-NT 2

DOTA-PEG4-Arg-Arg-Pro-Tyr-Ile-Leu

-2.40 ± 0.20

[104]

177

Lu-NT 3

DOTA-PEG4-Arg-Arg-Pro-Tyr-Tle-Leu

-2.25 ± 0.03

[104]

177

Lu-NT 4

DOTA-PEG4-Arg-Lys-Pro-Tyr-Ile-Leu

-2.10 ± 0.10

[104]

177

Lu-NT 5

DOTA-PEG4-Lys-Arg-Pro-Tyr-Ile-Leu

-2.08 ± 0.01

[104]

177

Lu-NT 6

DOTA-PEG4-Lys-Lys-Pro-Tyr-Ile-Leu

-2.00 ± 0.10

[104]

[68Ga]4

NODA-PEG6-Lys-Pro-Tyr-Tle-Leu

-4.20

[105]

[68Ga]6

DOTA-(ζ)Lys-Lys-Pro-Tyr-Tle-Leu

-4.00

[105]

[68Ga]8

NODA-PEG6-(ζ)Lys-Lys-Pro-Tyr-Tle-Leu

-4.10

[105]

177

DOTA-Lys-Pro-(N-Me)Arg-Arg-Pro-Dmt-Tle-

−3.45 ± 0.05

[45]

−3.15 ± 0.05

[45]

−3.11 ± 0.05

[45]

−2.99 ± 0.03

[45]

DOTA-Lys-DLeu-Dleu-Dleu-Dleu-Pro-(N-Me) −2.53 ± 0.02

[46]

Lu-N0

Leu-OH
177

Lu-N1

DOTA-β-Ala-Lys-Pro-(N-Me)Arg-Arg-ProDmt-Tle-Leu-OH

177

Lu-N2

DOTA-5-Ava-Lys-Pro-(N-Me)Arg-Arg-ProDmt-Tle-Leu-OH

177

Lu-N3

DOTA-8-Aoc-Lys-Pro-(N-Me)Arg-Arg-ProDmt-Tle-Leu-OH

177

Lu-K2

Arg-Arg-Pro-Dmt-Tle-Leu-OH
177

Lu-K4

DOTA-DLeu-Dleu-Lys-Dleu-Dleu-Pro-(N-Me) −2.59 ± 0.02

[46]

Arg-Arg-Pro-Dmt-Tle-Leu-OH
177

Lu-K6

DOTA-DLeu-Dleu-Dleu-Dleu-Lys-Pro-(N-Me) −2.63 ± 0.01
Arg-Arg-Pro-Dmt-Tle-Leu-OH

[46]
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1.5

The optimization of NT-based radiopharmaceuticals to
decrease renal uptake
The

high

in

vivo

NTR1-targeting

capabilities

of

NT-based

radiopharmaceuticals has resulted in significant interest for the development of
diagnostic and therapeutic agents based on this platform [44,45]. However, the high,
non-specific kidney uptake, due to renal clearance, has been a concern with regard to
the development of NTR1-targeted radiotherapeutic agents [44,45]. This situation is
not new to the field of receptor-targeted peptide when considering that other peptides
in clinical development, such as bombesin, somatosatin, minigastrin and CCK analogs,
have been comprised by the high non-specific kidney uptake [106]. The significant
amount of radioactivity remained in the kidney post-injection for peptide receptor
radionuclide therapy (PPRT) could cause renal toxicity and possibly damage the
kidneys after treatment [107].
To further explain the reason of high kidney uptake in the next section, the
general process of radiolabeled peptides after administration has been provided here
[106,108]. After the injection and distribution, the majority of the radiolabeled peptides
were excreted to the urine via kidney. The first step for kidney excretion is the
glomerular filtration. The glomerulus is consisted of the loopy arteriole, where the ions,
amino acids, glucose and water will be leaked under high pressure through the
fenestrated endothelial cells on the vessel wall (with holes). During this process, the
radiolabeled peptides are small enough to be efficiently filtered out from the blood in
glomerulus to the Bowman’s Capsule and entered proximal tubule [106]. At the
proximal tubule, majority of the filtered radiolabeled peptides will be reabsorbed back
to blood, by multiple transport mechanisms (e.g., receptor-mediated endocytosis and
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pinocytosis) [106,109]. The filtrate and water that are not reabsorbed at the proximal
tubule will be excreted to the urine.
1.5.1 Mechanisms of renal uptake
The mechanism underlying the high kidney uptake of radiolabeled peptides has
been of great interest in order to understand how to limit or decrease the kidney
absorption of these agents. Based on our current understanding, two major uptake
pathways have been identified: (1) receptor-mediated endocytosis by megalin and (2)
fluid-phase

endocytosis

(pinocytosis)

[106,107,109–111].

Other

membrane

transporters, such as organic anion and organic cation transporter, have been
investigated, but none have yet to be found to be prominent players in the uptake of
peptide-based

radiopharmaceuticals

[107].

Using

[111In-DTPA]octreotide,

a

somatostatin analogue, de Jong and co-workers determine that the primary site of
uptake in the kidney was the cortex [111]. Their subsequent work unambiguously
demonstrated that megalin, a multiligand receptor found on many absorptive cell types,
was a major contributor to radiolabeled somatostatin retention in the kidney [112].
Courtoy and Jamar’s group first identified the equal role of pinocytosis to the renal
uptake of radiolabeled somatostatin analogues by using the proximal tubule-derived
opossum kidney (OK) cell line [113]. Though the initial work identifying these uptake
mechanism centered on somatostatin analogs, the same mechanisms of uptake have
been

shown

to

be

relevant

for

all

peptide-based

radiopharmaceuticals

[22,106,107,110,114]. A more detailed discussion concerning the megalin-mediated
endocytosis and pinocytosis mechanisms are presented below.
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1.5.1.1 Receptor-mediated endocytosis via megalin receptor
The biodistribution of radiolabeled NT analogs in the kidneys has shown the
same pattern of uptake as other radiopeptides (e.g., somatostatin, bombesin,
neurotensin, minigastrin and CCK analogues), namely high retention in the cortex and
low retention in the outer and inner medulla of the kidneys [22]. The high accumulation
of radiopeptides in the cortex has supported the hypothesis that megalin, which is
expressed predominately in the cortex, is one of the main uptake mechansims. Megalin
is a large, membrane-associated receptor (600 kDa) that is mostly expressed in the
proximal tubule and involved in the reabsorption of numerous endogenous substances
[106,110]. Unfortunately, numerous studies have demonstrated that megalin also has
high affinity for many peptide-based radiopharmaceuticals [109]. In one study, the
renal uptake of radiolabeled peptides was significantly reduced after pre-incubation
with known megalin ligands, such as albumin or receptor-associated protein (RAP)
[107]. In addition, the role of megalin-mediated kidney uptake of radiolabeled peptides
was

further

demonstrated

with

the

significant

decrease

of

uptake

of

[111In-DTPA]octreotide in a megalin-deficient mouse model compared to wild-type
mice [112]. Similar findings were observed when evaluating the renal uptake of
111

In-neurotensin, exendin and minigastrin in megalin-deficient mice compared to

wild-type mice [106]. While our understanding of megalin ligand-selectivity is
imperfect, studies to date have suggested that the positive charge state of most
receptor-targeted peptide could be a major contributing factor in the uptake by the
negatively charged megalin receptor [107].
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1.5.1.2 Pinocytosis (fluid-phase endocytosis)
Another transport mechanism that has been shown to contribute to the kidney
uptake of radiolabeled peptides is fluid-phase endocytosis (pinocytosis) [107,113].
Using lucifer yellow, a pinocytosis marker, Courtoy and Jamar’s group demonstrated
that a fluorescent somatostatin analog was taken up into proximal tubule endothelial
cells by pinocytosis [113]. Following this study, Trejtnar and colleagues further proved
the key role of pinocytosis in the renal uptake of several radiolabeled peptides by in
vitro cellular studies [107]. They found that pre-incubation with an irreversible and
selective pinocytosis inhibitor, rottlerin, significantly decreased pinocytotic uptake of
several radiolabeled peptides, including

177

Lu-labeled somatostatin, gastrin and

bombesin analogs. Although the radiolabeled NT analogs were not tested in these
studies, the generality of the uptake of numerous radiolabeled peptides supports the
hypothesis that pinocytosis likely contributes to the accumulation of NT-based analogs
in the renal proximal tubules [107].
1.5.2 Impact of charge and charge distribution on NT uptake in the kidney
To decrease the unfavorable kidney uptake of radiopeptides, the possible
factors that influence the kidney uptake have been investigated. The impact of the
charge state of radiopeptides on renal uptake has been reported by several different
groups [17,22,27,107,115,116]. These studies revealed that the kidney uptake of these
radiolabeled peptides were linearly increased with the number of charged amino acids
[22,116]. For example, in one study which evaluates the addition of a negatively
charged amino acid (i.e., Glu) to a radiolabeled bombesin construct, the decrease in net
charge decreased the kidney uptake [117]. In contrast, increasing the positive charge of
a somatostatin analog with the addition of basic amino acids increased the renal
retention [106,115]. Considering the megalin discussion above, a large portion of the
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renal uptake of radiolabeled peptides is carried out through a megalin-mediated process
and this process is influenced by the charge of the peptide. Based on these and other
studies, it seems highly likely that charge would be a factor in the uptake of
NTR1-targeted agents. Recently, we have expanded on the investigation of the
influence of charge by investigating how charge distribution in a radiolabeled NT
analog could affect biological performance including its renal retention. Specifically,
we designed NT analogs with the same overall charge state, but translated the charged
amino acid (Lys) away from the targeting pharmacophore. A complete discussion of
this study can be found in Chapter 3.
1.5.3 Strategies for reducing kidney uptake
Strategies to decrease the kidney uptake have been actively pursued. Some
investigations have focused on modifying the peptide, particularly the charge state, to
decrease renal retention. These modifications have general focused on substitution,
addition or removal of charged amino acids [115,117]. However, these modifications
can many times result in the loss of binding affinity and/or suboptimal biodistribution
profiles. An alternative that has been actively explored is the utilization of blocking
agents to reduce renal retention. Most of these agents are believed to reduce kidney
uptake by blocking megalin-mediated uptake. Below are examples of the most
commonly used approaches.
1.5.3.1 Arg and Lys administration
The administration of positively-charged amino acids, such as Arg, Lys,
poly-L-lysine, D-Lys and their combination have been shown effective at decreasing
the kidney uptake of some positively-charged radiopeptides [118–120]. The
positively-charged Arg and Lys competitively bind to the megalin and saturate the
receptor to decrease the non-specific binding of positively-charged radiopeptides (e.g.,
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NT-based peptides). For example, a clinical study using a targeted radiotherapeutic
somatostatin analog demonstrated that the co-administration of Lys and Arg
significantly decreased the renal uptake in patients [120]. Currently, co-infusion of
basic charged amino acids (e.g., Arg and Lys) is the standard and common strategy to
protect the kidney during PRRT [106].
1.5.3.2 Other strategies
Besides the administration of Arg or Lys, pretreatment of albumin (a natural
ligand for megalin) at low concentrations (0.5mg/ml) decreased kidney uptake for
several investigated radiolabeled peptides (e.g.,
111

111

In-octreotide,

111

In-exendin and

In-minigastrin) [114]. The inhibitory effect of the administration of albumin was

proportionally related to the concentration that was employed. Other megalin blocking
agents such as RAP [107] and fragments of albumin have also demonstrated the
capability of decreasing the kidney uptake of radiopeptides [114]. Other strategies that
have been investigated to reduce renal uptake and retention of the proximal tubule
endothelial cells include: disruption of microtubule formation by colchicine or
nocodazole [121,122], the administration of NH4Cl to neutralize the negatively charged
binding site of megalin [123,124], and the inhibition of the citric acid cycle to disrupt
the endocytic energy supply by maleate [123].
The studies on the mechanisms of renal uptake and the strategies that could
efficiently decrease retention are still ongoing. More studies are needed to investigate if
other transporters play a role in this endocytic process. Based on what is currently
known of the proximal tubule cell absorption, there is no doubt that much work will be
focused on the development of better methods and techniques for avoiding the retention
of NTR1-targeted agents as well as other receptor-targeted peptides .
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1.6

Current clinical studies
Although NT-based radiopharmaceuticals has been under development for

more than 30 years, only two clinical studies have been carried out [41,60]. In 2003,
the first clinical study investigating an NTR1-targeted agent was reported.
99m

Tc-NT-XI (see Table 1.5) was evaluated in four patients with pancreatic cancer.

NTR1-mediated uptake was found to correspond to the NTR1-expression of the
pancreatic tumors. Unfortunately, the overall pancreatic tumor uptake was relatively
low compared to the non-target uptake in the intestine and kidneys, as well as to a
lesser extent, in the liver, spleen and bone marrow. Eight years later, an additional
clinical study was carried out using

99m

Tc-Demotensin VI (N4-β-Ala-Arg-Dab-Pro-

Tyr-Tle-Leu-OH) in patients with a variety of tumors types, including pancreatic
adenocarcinoma (n =4), small cell lung cancer (SCLC) (n =4), non-small cell lung
cancer (NSCLC) (n= 4), and colon carcinoma (n= 2). Tumor uptake was negligible
for all patients. However, this was attributed to the rapid degradation of this analog in
vivo and does not necessarily reflect on the potential of NTR1-targeted agents. These
two clinical studies revealed that further development of NTR1-targeted agents is
needed to reduce non-target retention, increase in vivo stability and determine the true
potential of these agents for clinical translation.

1.7

Summary and current proposal
Due to its role as a growth pathway for cancer cell proliferation, invasion and

migration, NTR1 has been shown to be overexpressed in many prominent cancers,
including pancreatic, breast, and colon cancers. The high occurrence of NTR1 in these
tumors provides a viable target for receptor-specific diagnosis and therapy. The
NTR1-targeted ligands, typically based on the NT peptide, has been conjugated to
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various radiometals and investigated for the diagnosis and therapy of NTR1-positive
tumors. As discussed above, the development of NT-based radiopharmaceuticals has
been comprised by the rapid degradation in vivo, reduced binding affinity due to the
chelator (e.g., DOTA) and the high uptake in non-target tissues (e.g., kidney). To
investigate solutions for these drawbacks and improve the biological performance of
NT-based radiopharmaceuticals, we focused on approaches to better elucidate the
structure-activity relationships and improve the potential of NTR1-targeted agents.
In this dissertation, the work in the following chapters demonstrated the
possible strategies that could be employed to increase the biological performance of
NT-based radiopharmaceuticals. Specifically, we investigated: (1) the insertion of
various spacers to optimize binding affinity, (2) the effect charge distribution of the
NTR1-targeted agent had on pharmacokinetic performance and (3) the effect
co-administration of enzyme inhibitors and competitive substrates had on the in vivo
stability of an NTR1-targeted agent. Through the strategies and methods that we have
investigated, we hope to move the field toward a better understanding of
NTR1-targeted agents and improve the potential of these agents for clinical
applications.
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Chapter 2:
Evaluation of DOTA-Chelated Neurotensin Analogs with
Spacer-enhanced Biological Performance for
Neurotensin-Receptor-1-Positive Tumors Targeting
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2.1

Abstract
Neurotensin receptor 1 (NTR1) is overexpressed in many cancers types.

Neurotensin (NT), a 13 amino acid peptide, is the native ligand for NTR1 and exhibits
high (nM) affinity to the receptor. Many laboratories have been investigating the
development of diagnostic and therapeutic radiopharmaceuticals for NTR1-positive
cancers based on the NT peptide. To improve the biological performance for targeting
NTR1, we proposed NT analogs with DOTA chelation system and different lengths of
spacers.
We synthesized four NTR1-targeted conjugates with spacer lengths from 0 to
9 atoms (null (N0), β-Ala-OH (N1), 5-Ava-OH (N2), and 8-Aoc-OH (N3)) between
the DOTA and the pharmacophore. In vitro competitive binding, internalization and
efflux studies were performed on all four NT analogs. Based on these findings,
metabolism studies were carried out on our best performing conjugate,

177

Lu-N1.

Lastly, in vivo biodistribution and SPECT/CT imaging studies were performed using
177

Lu-N1 in an HT-29 xenograft mouse model.
As shown in competitive binding assay, the NT analogs with different spacers

(N1, N2 and N3) exhibited lower IC50 values than the NT analog without a spacer
(N0). Furthermore, N1 revealed higher retention in HT-29 cells with more rapid
internalization and slower efflux than the other NT analogs. In vivo biodistribution
and SPECT/CT imaging studies of

177

Lu-N1 demonstrated excellent accumulation

(3.1 ± 0.4 %ID/g) in the NTR1-positive tumors at 4 h post-administration.
The DOTA chelation system demonstrated some modest steric inhibition of
the pharmacophore. However, the insertion of a 4-atom hydrocarbon spacer group
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restored optimal binding affinity of the analog. The in vivo assays indicated that
177

Lu-N1 could be used for imaging and radiotherapy of NTR1-positive tumors.

2.2

Introduction
The neurotensin receptor 1 (NTR1) is a G protein-coupled receptor of the

neurotensin receptor family, of which there are three known members [77]. NTR1 has
been shown to be up-regulated in numerous cancer types, including colon [57], breast
[53], and pancreatic cancer [52]. The overexpression of NTR1 has been attributed to
cancer cells as a crucial growth signaling pathway [59,125]. Studies have shown a
strong link between NTR1 expression and the progression of many cancer types
[54,57,59].
One area of NTR1 drug development being actively explored is
NTR1-targeted diagnostic and therapeutic radiopharmaceuticals. The majority of
these agents are based on neurotensin (NT), a 13-amino-acid peptide which exhibits
nanomolar binding affinity to NTR1 [126]. The C-terminus of NT is responsible for
binding to NTR1, thus research has focused largely on employing NT(8-13) and
NT(6-13) fragments in drug development [68]. One major obstacle that has hampered
the development of NTR1-targeted radiopharmaceuticals is the rapid proteolytic
degradation of the NT in serum. The main degradation sites are the Arg8-Arg9,
Pro10-Tyr11 and Try11-Ile12 bonds in the NT structure [127]. To enhance the potential
of NTR1-targeted radiopharmaceuticals, Schubiger, Garcia-Garayoa and others have
reported promising strategies to metabolically stabilize the NTR1-targeted agents
[42–44]. These modifications consist of replacing selected amino acids at the
degradation sites with non-natural counterparts to inhibit proteolytic cleavage. Among
these stabilizing modifications, replacement of a secondary amide with a tertiary

40
amide (N-CH3) at the Arg8 position, replacement of Tyr11 with 2,6-dimethyl tyrosine
(Dmt), and replacement of Ile12 with tert-leucine (Tle), have been shown to
substantially inhibit degradation and improve in vivo stability [44,96].
A principal chelator used in the design of radiometal-based theranostic agents
is DOTA [44]. The primary reason for the extensive utilization of this macrocycle is
its inherent in vivo stability with a variety of clinically relevant radiometals. The
incorporation of DOTA on the N-terminus of the pharmacophore has been
accomplished with diverse receptor-avid peptides [128]. However, for some peptides,
placement of the DOTA chelation system too close to the pharmacophore can
sterically interfere with the binding of the agent to the receptor of interest [129]. In
this circumstance, inclusion of a linking group to increase the distance between DOTA
and the pharmacophore can restore optimal binding [130,131].
In this study, we investigated the extent to which distance between the DOTA
chelation system and a NT(6-13) peptide fragment affects binding affinity. The
NT(6-13) analog ([(N-α-Me)Arg8,Dmt11,Tle12]NT(6-13)) chosen for this study
includes all three of the stabilizing modifications listed above. Hydrocarbon linking
groups of various lengths (0 – 9 atoms) were incorporated between the DOTA
chelation system and the N-terminus of the NT pharmacophore. Once in hand, the in
vitro binding and cellular uptake properties of the NTR1-targeted conjugates were
investigated in the NTR1-positive HT-29 human colon cancer cell line. Based on
these results, we report the preliminary biodistribution and SPECT/CT studies of our
most promising radioconjugate.
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2.3

Methods

2.3.1 Materials
Acetonitrile,

formic

N,N-dimethylformamide
carbodiimide

(DCC)

acid,

(DMF),
,

N,N-diisopropylethylamine

dichloromethane

N-methylpyrrolidone

(DCM),

(NMP),

(DIEA),

N,N'-dicyclohexyl-

4-(2-hydroxyethyl)-1-

piperazineethane-sulfonic acid (HEPES), bovine serum albumin (BSA) and sodium
dodecyl sulfate (SDS) were purchased from Fisher Scientific (Fair Lawn,
NJ).

Fluorenylmethyloxycarbonnyl

(Fmoc)-protected

natural

amino

acids,

Fmoc-β-Ala-OH, Fmoc-Leu-Wang resin (100-200 mesh), and (1-cyano-2-ethoxy2-oxoethylidenaminooxy)

dimethylamino-morpholino-carbenium

hexafluoro-

phosphate (COMU), were purchased from NovaBiochem (Hoherbrunn, Germany).
Fmoc-N-Me-Arg(Pbf)-OH was produced by ChemPep, Inc. (Wellington, FL).
Fmoc-2,6-dimethyl-L-tyrosine (Dmt) was from Ontario Chemicals, Inc (Guelph, ON,
Canada). Fmoc-Tle-OH, Fmoc-8-Aoc-OH, and Fmoc-5-Ava-OH were purchased
from CreoSalus (Louisville, KY). Lutetium-177 chloride (177LuCl3) was obtained
from Perkin Elmer (Waltham, MA) with a specific activity of 32.3 Ci/mg. Naturally
abundant

lutetium

chloride

(natLuCl3),

triisopropylsilane

and

3,6-dioxa-1,8-octanedithiol were from Sigma-Aldrich (St Louis, MO). Neurotensin
(NT) was purchased from American Peptide, Inc. (Sunnyvale, CA). McCoy’s 5A
medium (1X; Iwakata & Grace Mod.) with L-glutamine was obtained from
Mediatech, Inc. (Manassas, VA). TrypLETM Express was purchased from Invitrogen
(Grand Island, NY).
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2.3.2 Cell culture
The human colon cancer cell line HT-29 was obtained from American Type
Culture Collection (Manassas, VA) and cultured under vendor-recommended
conditions. Cells were passaged twice weekly in McCoy’s 5A medium supplemented
with 10% FBS, 100 IU/ml penicillin and 100 μg/ml streptomycin at 37 °C in a
humidified incubator containing 5% CO2.
2.3.3 Xenograft models
All animal experiments were conducted in accordance with the Principles of
Animal Care outlined by the National Institutes of Health and approved by the
Institutional Animal Care and Use Committee of the University of Nebraska Medical
Center.

Eight-week-old

Institute

of

Cancer

Research

severely

combined

immunodeficient (ICR SCID) mice were obtained from Charles River Laboratories
(Wilmington, MA). Animals were housed five per cage in a light- and
temperature-controlled environment. Food and water were given ad libitum. Bilateral
HT-29 tumors were induced by subcutaneous injection of 4.0×106 cells in Matrigel
(BD Biosciences). The tumors were allowed to grow for 2-3 weeks reaching maximal
1 cm in diameter before the mice were utilized in pharmacokinetic studies.
2.3.4 Solid-phase peptide synthesis (SPPS)
Peptides were synthesized on an automated solid-phase Liberty microwave
peptide synthesizer from CEM (Matthews, NC), employing traditional Fmoc
chemistry. Briefly, the Fmoc-Leu-Wang resin (100 µmol of the resin-substituted
peptide anchors) was deprotected by piperidine, resulting in the formation of a
primary amine from which the C-terminus of the growing peptide was anchored.
Fmoc-protected amino acids (300 µmol) were activated with COMU and sequentially
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conjugated to the resin. The resulting peptide was orthogonally deprotected and
cleaved from the resin by shaking in a cocktail consisting of triisopropylsilane
(0.125 ml), water (0.125 ml), 3,6-dioxa-1,8-octanedithiol (0.125 ml), and
trifluoroacetic acid (4.625 ml) for 3 h. The cleaved peptide was subsequently
precipitated and washed thrice using cold (0 °C) methyl-tert-butyl ether (40 ml×3).
The crude conjugate was dried by a CentriVap concentrator and weighed.
2.3.5 HPLC purification and analysis methodology
HPLC/MS analyses were performed on a Waters (Milford, MA) e2695 system
equipped with a Waters 2489 absorption detector and a Waters Q-Tof Micro
electrospray ionization mass spectrometer. Sample purification for in vitro studies
was performed on a Phenomenex (Torrance, CA) Jupiter 10 µm Proteo 250 × 4.6 mm
C12 column with a flow rate of 1.5 mL/min. For bulk sample purification, a
Phenomenex Jupiter 10 µm Proteo 250 × 10 mm C12 column was used with a flow
rate of 5.0 mL/min. HPLC solvents consisted of H2O containing 0.1% formic acid
(solvent A) and acetonitrile containing 0.1% formic acid (solvent B). For unlabeled
and

177/nat

Lu-conjugates of N0 and N1, an initial gradient of 95% A: 5% B linearly

decreased to 85% A: 15% B over a 15-minute time period. For unlabeled and
177/nat

Lu-conjugates of N2, an initial gradient of 92% A: 8% B linearly decreased to

87% A: 13% B over a 15-minute time period. For unlabeled and

177/nat

Lu-conjugates

of N3, an initial gradient of 90% A: 10% B linearly decreased to 85% A: 15% B over
a 15-minute time period. At the end of the run time for all HPLC experiments, the
column was flushed with the gradient 5% A: 95% B and re-equilibrated to the starting
gradient.
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2.3.6 Labeling with natLuCl3
Naturally abundant natLu was used to substitute for 177Lu in the ES-MS and in
vitro binding studies. A sample of conjugates (0.10 mg, 0.06 μmol ) was dissolved in
ammonium acetate buffer (0.5 M, 200 μL, pH 5.5) and mixed with a solution of
nat

LuCl3 (1.7mg, 6 μmol). The solution was heated for 60 min at 90 °C. After cooling

to room temperature,

nat

Lu-conjugates were then peak purified by RP-HPLC in the

same conditions above. All

nat

Lu-conjugates were ≥ 95% pure before mass

spectrometric characterization and in vitro binding studies were performed.
2.3.7 Radiolabeling with 177LuCl3
A sample of the conjugates (50 µg, 30 nmol)) was dissolved in ammonium
acetate buffer (0.5 M, 100 μL, pH 5.5).

177

LuCl3 (37 MBq, 1 mCi, 0.18 nmol) was

added to the vial containing the conjugate, and the solution was heated for 60 min at
90 °C. To separate radiolabeled peptides from unlabeled peptides on HPLC, 4-5 mg
CoCl2 were then added and incubated for 5 min at 90 °C to increase the
hydrophobicity of unlabeled conjugates[132]. After cooling to room temperature,
evaluation and purification of radiolabeled conjugate were performed on a Waters
1525 binary pump equipped with a Waters 2489 absorption detector and a Bioscan
(Poway, CA) Flow Count radiometric detector system. The collected radioconjugate
was concentrated with an Empore (Eagan, MN) C18 high performance extraction disk
followed by elution with ethanol/sterile saline solution (6:4, 400 μL) to provide the
radiolabeled conjugates in high purity.
2.3.8 Distribution coefficient
The distribution coefficient was determined (n = 6, 2 technical (tech) and
3 biological (bio) repeats) for each

177

Lu-labeled conjugate. In a 1.5 ml centrifuge

tube, 0.5 mL of 1-octanol was added to 0.5 mL phosphate-buffered saline (pH 7.4)
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containing the radiolabeled peptide (500,000 cpm). The solution was vigorously
stirred for 2 min at room temperature and subsequently centrifuged (8000 x g, 5 min)
to yield two immiscible layers. Aliquots of 100 µL were taken from each layer and
the radioactivity of each was quantified by an LTI (Elburn, IL) Multi-Wiper nuclear
medicine gamma counter.
2.3.9 Receptor saturation
Receptor saturation studies were performed (n = 6, 2 tech and 3 bio repeats)
using

177

Lu-N1 on the human colon cell line HT-29. HT-29 cells (1×106) were

suspended in 1.5 ml low retention centrifuge tubes with 100 µl McCoy’s medium
(pH 7.4, 4.8 mg/mL HEPES, and 2 mg/mL BSA).

177

Lu-N1 (200,000 cpm, 100 µl)

and a series of 100 µl N1 concentrations ranging from 0.469 nM to 120 nM were
added for 45 min at 4 °C. Non-specific binding was determined using 3 µM N1 in the
presence of the radioligand. The specific activity was determined as total binding
activity minus non-specific binding. At the end of the incubation time, cells were
aspirated and washed five times with cold medium and the remaining radioactivity
was measured by gamma counter. Non-linear regression analysis was then performed
using GraphPad Prism 5 (La Jolla, CA) to determine the Bmax and Kd values for each
experiment.
2.3.10

In vitro competitive binding studies
For in vitro binding studies, the half maximal inhibitory concentration (IC50)

for each conjugate was determined (n = 6, 2 tech and 3 bio repeats) for each
177

Lu-labeled conjugate using the human colon cancer cell line, HT-29. In these

studies,

177

Lu-N1 served as the control and as the radioligand for comparing the

relative effectiveness of the conjugates (N0-3 and NT). Briefly, HT-29 cells (~1×106)
were suspended in 100 µl McCoy’s medium (pH 7.4, 4.8 mg/mL HEPES, and
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2 mg/mL BSA) and incubated at 37 °C for 45 min in the presence of radiolabeled
177

Lu-N1 (100,000 cpm, 100 µl) and various concentrations of the unlabeled

conjugates and

nat

Lu-conjugates (100 µl). At the end of the incubation, the cells were

centrifuged, aspirated and washed with media five times. The cell-associated
radioactivity was measured using a gamma counter and the IC50 values determined by
nonlinear regression using the one-binding site model of GraphPad Prism 5 (La Jolla,
CA).
2.3.11

In vitro internalization and efflux studies
Internalization studies were performed (n = 6, 2 tech and 3 bio repeats) for

each

177

Lu-labeled conjugate using HT-29 cells in 1.5-ml centrifuge tubes. HT-29

cells (~1×106) were suspended in 100 µl McCoy’s media (pH 7.4, 4.8 mg/mL HEPES,
and 2 mg/mL BSA). Cells were incubated for various times up to 2 h at 37°C in the
presence of 100,000 cpm of each

177

Lu-radioconjugates. During the incubation, at

time points 15, 30, 60 and 120 min, cells were washed five times with media to
remove the unbound peptide. Surface-bound radioactivity was removed by washing
the cells twice with an acidic buffer (50 mM glycine-HCl/0.1 M NaCl buffer, pH 2.8).
The amount of radioactivity in each cellular pellet was measured as the internalized
fraction by gamma counter.
For efflux studies, HT-29 cells (~1×106) were incubated in six-well plates
overnight. On the day of the experiment, HT-29 cells were first incubated for 2 h at
37°C in the presence of 100,000 cpm of each of the 177Lu-radioconjugates to reach the
plateau of internalized radioactivity. Upon completion of the incubation, cells were
washed five times with medium to remove the unbound peptide. Then, fresh medium
was put in each well as the reservoir for efflux. At 0, 1, 2, 4 and 24 h, the medium for
each time point was harvested for quantitative analysis of ligand efflux.
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Surface-bound radioactivity was removed by washing the cells twice with an acidic
buffer (50 mM glycine-HCl/0.1 M NaCl buffer, pH 2.8). The cells were then lysed at
37°C using a 10 % aqueous SDS solution to quantify the remaining internalized
fractions. The radioactivity in the effluxed, surface-bound and internalized fractions
for each radioconjugate was determined using a gamma counter. The effluxed fraction
is expressed as a percentage of the total amount, which is the sum of the effluxed,
surface-bound and fraction remaining in the cell.
2.3.12

Metabolic stability
The stability of

177

Lu-N1 in human serum and cell medium was determined.

Conditioned medium refers to medium in which cells were cultured at least for one
day, as medium obtained under these conditions is believed to contain proteases
excreted from HT-29 cells. The conditioned medium was prepared by centrifuging at
4000 x g for 2 min to remove cells or cell debris. Briefly, 50 µL of HPLC-purified
peptide in PBS (1.85 MBq, 50 µCi, 15 ng) was added to 50 µL human serum (MP
Biomedicals, LLC (Solon, OH)) or conditioned medium and incubated at 37 °C for up
to 24 h. After the incubation, 100 µL of a mixture of ethanol and acetonitrile
(v/v = 1:1) was added to precipitate the serum proteins. The resulting mixture was
centrifuged at 12000 x g for 10 min. The supernatant was collected and purged with
N2 gas for 20 min to remove the ethanol and acetonitrile. The resulting sample was
dissolved in 100 µL water and injected into RP-HPLC for analysis using the gradient
described above.
2.3.13

In vivo biodistribution studies
Biodistribution studies were carried out using HT-29 tumor bearing SCID

mice. Each mouse (average weight, 20 g) received an intravenous bolus, via the tail
vein, of the radio-RP-HPLC purified 177Lu-N1 (280 kBq, 7.5 µCi, 2.25 ng) in 100 μL
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of saline. Four-hour post injection, the mice were sacrificed and the amount of
radioactivity in the tumors and other tissues (blood, heart, lung, stomach, pancreas,
spleen, liver, kidneys, small intestine and colon) were counted by gamma counter.
The excised tissues were weighed and results were expressed as percentage of
injected dose per gram of tissue (%ID/g). Biodistribution radiation was measured with
a NaI (Tl) well detector from AlphaSpectra, Inc. (Grand Junction, CO). Blocking
studies were carried out by co-injection with excess unlabeled N1 (250 μg).
SPECT/CT imaging with 177Lu-N1

2.3.14

For SPECT/CT imaging studies, HT-29 tumor xenograft mice were injected
i.v. with

177

Lu-N1 (37 MBq, 1 mci, 300 ng) in 100 μL of saline and sacrificed for

scanning 2 h post-injection. Images were acquired for 1 h using a FLEX Triumph
single photon emission computed tomography system/X-ray computed tomography
(SPECT/CT) and software (Gamma Medica, Inc., Northridge, CA).
2.3.15

Statistical analysis
Comparisons of each two groups for IC50, internalization and efflux studies,

were analyzed by the unpaired two-tailed Student’s t test, and P values of less than 0.05
were considered statistically significant.

2.4

Results

2.4.1 Synthesis and radiolabeling
Four

NT

analogs

were

synthesized

by

SPPS

using

the

DOTA-X-[(N-α-Me)Arg8,Dmt11,Tle12]NT(6-13) paradigm depicted in Figure 2.1,
where X represents a series of hydrocarbon linkers of increasing length. Initial
attempts at the synthesis of the peptides by SPPS gave unacceptably poor yields.
Evaluation of the crude material by LC-MS revealed that a significant portion was
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composed of terminated peptide chains and deletion peptides that originated at or after,
respectfully, the N-methyl arginine. With the premise that the steric of the secondary
amine were negatively affecting coupling yields, we made the following
modifications to our SPPS protocol: 1) for all coupling reaction, the concentration of
the coupling agent, COMU, was increased 4-fold, from 0.125 M to 0.5 M; 2) the time
allowed for Fmoc-deprotection of all amino acids was increased 2-fold, from 3 min to
6 min; and 3) for the two amino acids directly following the N-methyl arginine, the
coupling time was increased from 5 min to 10 min and the reaction temperature was
increased from 75 °C to 95 °C. With these modifications, the isolated yields of
conjugates N0-3, after RP-HPLC purification, were substantially improved from less
than 1% to greater than 10%. The purified conjugates were subsequently labeled with
177/nat

LuCl3 (t½ = 6.75 days for

177

LuCl3) by co-incubation in an ammonium acetate

buffer (pH = 5.5) for 60 min at 90 °C. The radiochemical yields for
177

Lu-N1,

177

Lu-N2 and

177

177

Lu-N0,

Lu-N3 were 91%, 94 %, 98% and 95%, respectively.

RP-HPLC retention time, mass spectrometric identification and yields of the
unlabeled conjugates and natLu-conjugates are listed in Table 2.1.
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β-Ala

5-Ava

8-Aoc

Figure 2.1. Structures of the Lu-([(N-α-Me)Arg8,Dmt11,Tle12]NT(6-13) analogs
used in this study (Lu-N0, Lu-N1, Lu-N2 and Lu-N3).

51

Table 2.1. Characterization, Yields, and IC50 values of NT analogs.
Analog

MS Cal.

MS Obs. Retention
([M+H]+)

Yields

IC50 ± SD (nM)

Time (min)

N0

1469.9

1470.9

13.1

10.6%

52.3 ± 1.5

N1

1540.9

1541.9

13.9

11.1%

27.6 ± 1.3

N2

1568.9

1569.9

10.8

10.0%

20.8 ± 1.4

N3

1611.0

1611.9

11.3

10.2%

21.1 ± 1.7

nat

1641.9

1642.8

10.6

78.1%

47.2 ± 1.2

nat

1712.9

1713.8

11.7

71.2%

27.2 ± 1.1

nat

1740.9

1741.8

10.4

72.2%

24.3 ± 1.1

nat

1783.0

1783.8

9.6

86.7%

20.3 ± 1.2

NT

—

—

—

—

22.3 ± 1.2

Lu-N0
Lu-N1
Lu-N2
Lu-N3
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2.4.2 Distribution coefficient
To evaluate the impact of the hydrocarbon linkers on water solubility of the
radioconjugates, the octanol-PBS distribution coefficients at pH 7.4 were measured.
The log Doct/water values for

177

Lu-N0,

177

Lu-N1,

177

Lu-N2 and

177

Lu-N3 were

-3.45 ± 0.05, -3.15 ± 0.05, -3.11 ± 0.05 and -2.99 ± 0.03, respectively.
2.4.3 Receptor saturation
To establish the surface expression of the NTR1 on the HT-29 cell line, receptor
saturation studies were performed using

177/nat

Lu-N1.

177/nat

Lu-N1 bound well to the

surface of HT-29 cells, and this binding could be blocked with the addition of unlabeled
NT, thus implying the specific blockage of NTR1. From these studies, carried out at
4 °C to prevent receptor-mediated endocytosis, the NTR1 expression was found to be
85000 ± 1000 binding sites per HT-29 cell with a dissociation constant (Kd) of
42 ± 8 nM. The receptor saturation curve has been shown in Figure 2.2.
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Figure 2.2. Receptor saturation study for N1.
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2.4.4 In vitro competitive binding studies
The NTR1 binding affinity of the unlabeled conjugates and

nat

Lu-conjugates

was investigated by competitive binding studies using HT-29 cells. Both unlabeled
conjugates and

nat

Lu-conjugates demonstrated nanomolar binding affinities. The IC50

values for unlabeled N1, N2 and N3 were in the same range as full NT peptide. In
contrast, the IC50 value for unlabeled N0 was higher than that of NT (P < 0.01),
indicating lower binding affinity to the NTR1. A similar trend was observed for the
nat

Lu-labeled conjugates.

nat

nat

Lu-N1, natLu-N2 and natLu-N3 (P < 0.01) (Table 2.1).

Lu-N0 had the lowest affinity for the NTR1 relative to

2.4.5 In vitro internalization and efflux studies
The effect of the linker modifications on the rates of internalization (Figure 2.3)
and efflux (Figure 2.4) of the radioconjugates was investigated in HT-29 cells. The
cellular uptake of the radioconjugates, represented as a percentage of total activity
added, was evaluated at 15, 30, 60, and 120 min time points. The cellular uptake
consisted of internalized and surface-bound radioactivity. For 177Lu-N0, 177Lu-N2 and
177

Lu-N3, the internalization of these radioconjugates was essentially identical over the

initial 60 min time period. However, by 120 min post-incubation, a statistically
significant increase was observed with overall uptake of
177

177

Lu-N0 >

177

Lu-N2 >

Lu-N3 (3.69% ± 0.17%, 3.14% ± 0.10%, 2.74% ± 0.02%, respectively,

P < 0.0001 ). After the 15 min time point, 177Lu-N1 demonstrated substantially higher
levels of uptake (2.66% ± 0.02%) relative to the other radioconjugates. By the 120 min
time point,

177

Lu-N1 had the highest level of overall uptake with 4.38% ± 0.10% of

total activity added.
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Efflux studies were conducted to determine if a structure-activity relationship
exists with regard to the externalization of the internalized radioconjugates. The efflux
of these radioconjugates was investigated at the 1, 2, 4 and 24 h time points. At 1 h
post-incubation,

177

Lu-N2 demonstrated higher levels of effluxed radioactivity

(26% ± 0.8%) relative to the other radioconjugates (18-21%). However, the percentage
of externalized radioactivity was largely indistinguishable for all of the radioconjugates
investigated by 2 h. At the 4 h time point, the effluxed fraction for
(29% ± 0.4%) was lower than that for 177Lu-N0,

177

Lu-N2,

177

177

Lu-N1

Lu-N3 (33% ± 2.5%,

34% ± 0.9% and 36% ± 3.6%, respectively, P < 0.01). Overall, the percent of initial
internalized radioactivity effluxed from the cells ranged from 25-32 % by the 24 h time
point.
2.4.6 Metabolic stability
NT is known to be susceptible to serum proteases [127]. The targeting vector
used in our radioconjugates contains modifications to inhibit metabolic cleavage [44].
To establish if the structural modifications, the DOTA, or the N-terminal linker
altered metabolic stability, the stability of

177

Lu-N1 was investigated over a 24 h

period in PBS (not shown), the conditioned (used) medium, and human serum. Under
the conditions of the study, > 95% of the radioactivity was recovered for analysis
from each sample. Evaluation of these samples by radio-RP-HPLC revealed no
degradation over a 24-h time period (Figure 2.5).
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Figure 2.3. Time course following the uptake of 177Lu-radioconjugates, both
internalization and surface bound, by HT-29 cells. Values are
means ± SD (n = 6).
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Figure 2.4. Time course following the percent efflux of the internalized
177
Lu-radioconjugate by HT-29 cells. Values are means ± SD (n = 6).
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Figure 2.5. Stability of 177Lu-N1 in conditioned medium and human serum. Panel A:
chromatograph of 177Lu-N1 at start of the study, Panel B: chromatograph
of 177Lu-N1 after 24 h in conditioned medium, and Panel C:
chromatograph of 177Lu-N1 after 24 h in human serum. (x-axis: running
time for sample in mins; y-axis: the intensity of radioactivity)
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2.4.7 In vivo biodistribution and imaging studies
Based on the in vitro studies, 177Lu-N1 was deemed our best overall candidate
as a balance of the affinity, internalization and efflux. Therefore, 177Lu-N1 was chosen
for our preliminary in vivo investigation. Using the HT-29 xenograft mouse model, we
evaluated the in vivo biodistribution of
Figure 2.6. The i.v. administered

177

177

Lu-N1 at the 4 h time point, data given in

Lu-N1 effectively cleared from the blood

(0.02 ± 0.01 % ID/g) by 4 h. As expected given the hydrophilic nature of 177Lu-N1, the
clearance of radioactivity preceded largely through the renal system with
86.3 ± 6.0 %ID being excreted in the urine. As a result of the high renal clearance, the
kidneys exhibited significant retention (17.0 ± 2.2 %ID/g) at the 4 h time point. In
addition, both the small and large intestines, known to be NTR1-positive tissues,
exhibited retention of 1.4 ± 0.3 and 0.6 ± 0.1 %ID/g. This retention was largely found to
be NTR1-receptor mediated as it could be effectively blocked by co-injection of 250 µg
of unlabeled N1. For all other non-target tissues, 177Lu-N1 demonstrated good overall
clearance. At the 4 h time point, 177Lu-N1 displayed good in vivo tumor targeting and
retention, with a total accumulation of 3.1 ± 0.4 %ID/g. Accumulation in the tumor was
shown to be NTR1-receptor specific with 86.6 ± 4.5 % reduction in uptake upon
blocking. The ratio of tumor to blood was 123 ± 10, tumor to kidney was 0.2 ± 0.02,
tumor to liver was 9.3 ± 1.6, and tumor to muscle was 111 ± 10 (Table 2.2).
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Figure 2.6. Graph of the biodistribution data at 4 h p.i. for 177Lu-N1 in SCID mice
with HT-29 xenografts. The radioactivity accumulation is expressed as a
percentage of injected dose per gram (%ID/g). Values are means ± SD
(n = 5).
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Table 2.2. The Ratios of Tumor to Organs in Biodistribution Studies.
Tumor/organs

177

Tumor/blood

123.07 ± 9.81

3.91 ± 1.14

Tumor/kidney

0.17 ± 0.02

0.02 ± 0.00

Tumor/liver

9.33 ± 1.57

0.82 ± 0.16

Tumor/muscle

110.97 ± 10.34

2.03 ± 0.70

Lu-N1

blocking
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Using microSPECT/CT, we evaluated the imaging potential of 177Lu-N1 at 2 h
post-administration (Figure 2.7). Overall, the images correlated well with the
biodistribution studies carried out at the 4 h time point. With the exception of the
kidneys, little signal was observed in non-target tissues. The uptake of 177Lu-N1 in the
HT-29 tumors was clearly visible in the flanks of the mice. As expected, the kidneys,
the major pathway for biological clearance, were also readily observed.

2.5

Discussion
To date, NTR1-targeted peptides have been labeled with a number of clinically

relevant radiometals, such as 99mTc, 111In and 68Ga [44,96,103,133,134]. In recent years,
177

Lu, a theranostic radioisotope, has received increasing attention for potential clinical

applications due to its dual emission characteristics [48,135–137]. Upon decay,

177

Lu

emits therapeutic beta particles (Eavg = 133 keV) and gamma rays (113 and 210 keV,
6% and 10%) that are suitable for SPECT diagnostic imaging. Using

177

Lu allows the

potential for one radiopharmaceutical to be used as both a diagnostic and
radiotherapeutic, thus negating the need for a "matched-pair" system (e.g., 111In and 90Y)
for imaging and therapy. In general, the goal of any chelation system in a
radiopharmaceutical design is to retain the radionuclide during its in vivo lifetime. The
most common polyaminocaboxylate chelator utilized in NTR1-targeted agent design is
diethylenetriamine pentaacetic acid (DTPA) [31,44,84,138]. Unfortunately, DTPA
forms a complex with

177

Lu that in known to be unstable in vivo [139]. Conversely,

DOTA, due to its cyclic nature and steric inhibition, is known to form in vivo stable
177

Lu complexes, as demonstrated by numerous preclinical and clinical studies

[135,137,139]. At the same time, DOTA, when placed too closely to the
pharmacophore, has been shown to sterically inhibit the efficacy of receptor-targeted
peptides [37,129]. This has given us the impetus to investigate the impact of the
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Figure 2.7. SPECT/CT image of 177Lu-N1 in a HT-29 xenograft mouse model at 2 h
post-administration. Tu: tumor. Ki: kidney.
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177

Lu-DOTA

chelation-complex

on

the

performance

of

a

NTR1-targeted

pharmacophore (i.e., [(N-α-Me)Arg8,Dmt11,Tle12]NT(6-13)). To that end, we
synthesized and evaluated a series of these NTR1-targeted conjugates, structurally
depicted in Figure 2.1, with hydrocarbon linkers of 0, 4 (β-Ala), 6 (5-Ava) and 9 (8-Aoc)
atoms in length.
Under our standard SPPS conditions, initial attempts to synthesize the
conjugates, N0-3, in good yield was unsuccessful. Analysis of the crude material
revealed that the majority of the peptides formed were termination or deletion products
that stem from the incorporation of the N-methyl arginine at position 8. This is not too
surprising given that it is recognized that the formation of N-methylated amides can be
more difficult due to increased steric interference [140]. Adjustments to more vigorous
conditions (i.e., increased temperatures and longer reaction times) gave substantially
better yields of the desired peptides.
Receptor saturation studies of NTR1-positive HT-29 human colon cancer cells
revealed a receptor density of approximately 85,000 ± 1000 per cell and a Kd value of
42 ± 8 nM. Relative to literature, our determined Kd is higher than values reported from
other groups (1.5- 15 nM), but this moderate difference in values is likely attributable to
different experimental conditions (e.g., different ligands and temperature) [43,141,142].
Of particular note, our studies were performed at 4 °C to inhibit internalization; while,
literature reports were carried out at 24 or 37 °C. At these elevated temperatures, the
internalized activity would likely lead to an overestimate (lower value) in the
disassociation constant.
Based on the competitive binding assays, 177Lu-N0, as well as the unmetallated
peptide (N0), exhibited binding affinities that were roughly two fold lower than the
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corresponding analogs with hydrocarbon linkers. While this decrease in binding
affinity is relatively modest, it does show that the steric bulk of the DOTA affects the
NTR1 binding efficacy of the [(N-α-Me)Arg8,Dmt11,Tle12]NT(6-13) pharmacophore.
Inclusion of a 4 atom hydrocarbon linker (i.e., β-Ala) appears to alleviate the steric
inhibition of the chelator. Extension of the hydrocarbon linker beyond 4 atoms, as is the
case for N2, N3,

nat

Lu-N2 and

nat

Lu-N3, does not lead to substantial increases in

binding affinities. Interestingly, linker length does seem to play a more important role
in the internalization of the NTR1-targeted agents. For 177Lu-N1, the β-Ala linker gives
a substantially higher percentage of internalization relative to the other analogs. This is
177

followed by
out-performed

Lu-N0,

177

177

Lu-N2 and

Lu-N2 and

177

177

Lu-N3. It is interesting that

177

Lu-N0

Lu-N3 in spite of having a lower binding affinity. It

appears that even with high binding affinities, radioconjugates with longer hydrocarbon
linkers,

177

Lu-N2 and

177

Lu-N3, did not induce receptor-mediated internalization as

well as those with short or no hydrocarbon linkers, 177Lu-N1 and 177Lu-N0, respectfully.
Why the longer linker length would affect the ability of the pharmacophore to activate
the NTR1 is not clear. Relative to internalization, linker length had little effect on efflux
patterns of the radioconjugates. One noteworthy observation was the small decrease in
percentage efflux from 4 to 24 h time points. This suggests that externalized
radioactivity (decay normalized) is being recycled back into the cell. It seems unlikely
that this is through a receptor-mediated process, but may be attributable to pinocytosis
of effluxed radioactivity over time.
As

previously

mentioned,

the

[(N-α-Me)Arg8,Dmt11,Tle12]NT(6-13)

pharmacophore contains several modifications that significantly reduce enzymatic
degradation of the pharmacophore in vitro and in vivo [44]. Utilizing 177Lu-N1, our best
performing conjugate, the stability of this NTR1-targeted agent was evaluated in PBS,
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conditioned medium and human serum. No discernible degradation was observed from
these conditions over a 24 h period. This is expected based on the reported in vitro
stability data of analogs with similar modifications [44,84]. Thus, as anticipated, the
DOTA and the hydrocarbon linkers did not significantly alter in vitro stability of the
pharmacophore at least over the monitored time frame. While no in vitro degradation
was found for the [(N-α-Me)Arg8,Dmt11,Tle12]NT(6-13) peptide, Gruaz-Guyon and
co-workers have demonstrated that this pharmacophore does exhibit significant in vivo
metabolism in as little as 15 min post-injection [44]. This is an important consideration,
as others have pointed out, when evaluating in vivo data [85]. Although the stability
studies were not carried out with 177Lu-N0, 177Lu-N2 and 177Lu-N3, we assume similar
stabilities given the relative similarity of the radioconjugates.
177

Lu-N1 was chosen for preliminary in vivo investigations due to its superior in

vitro properties. At the 4 h time point, very little of the administered radioactivity
remained in the blood pool. The majority of the radioactivity (85% of the ID) was
cleared by the renal system which contributed to the substantial level of accumulation
in the kidneys (17.0 ± 2.2 %ID/g). Significant kidney accumulation was also observed
in the SPECT/CT imaging studies. Curiously, an analog (LB119) reported with the
same

[(N-α-Me)Arg8,Dmt11,Tle12]NT(6-13)

pharmacophore

demonstrated

substantially less renal accumulation (2.4 ± 0.2 %ID/g at 3 h p.i.) [44]. The distinct
differences between the two analogs may be explained by the charge of each
radioconjugate. On the N-terminal portion of

177

Lu-N1, the peptide contains three

positively charged amino acid residues (i.e. lysine and two arginines) yielding a total +2
charge for the radioconjugate. Comparatively, the N-terminus of LB119 has the same
three amino acids, but the charge of the lysine amino acid has been neutralized, by
conjugation, to yield a total +1 charge for the agent. For radiolabeled peptides, the

67
effect of charge and charge distribution on kidney accumulation has been well
established [106,110,117]. In general, radiolabeled peptides with increasing positive
charges tend to exhibit higher levels of kidney accumulation. This has been attributed,
at least in part, to non-specific uptake by the surface proteins megalin and cubilin [111].
The non-specific nature of

177

Lu-N1 uptake in the kidney was confirmed by

observation that blocking studies did not reduce accumulation.
177

Lu-N1

demonstrated

excellent

tumor

uptake

and

retention

with

3.1 ± 0.4 %ID/g at the 4 h time point. In comparison to LB119, 177Lu-N1 demonstrated
a 2 fold higher HT-29 tumor retention at 4 h than LB119 (1.41 ± 0.05 %ID/g) at 3 h
post-administration. Given the structural similarities of the pharmacophores, the
significant (P < 0.0001) increase in tumor uptake and retention of

177

Lu-N1 may be

attributable to the charge of the radioconjugate as observed with the kidneys.
Alternatively, this dissimilarity may be due to the purity of the prepared
radioconjugates.

177

Lu-N1 was obtained as a peak-purified product from HPLC

whereas LB119 was prepared without HPLC purification. The lack of purification of
LB119 likely resulted in a small amount of unlabeled conjugate being co-injected with
the radioconjugate, which may negatively impact NTR1 uptake. To what extent these
factors play into the higher retention of the

177

Lu-N1 is not clear at this time. Small

animal SPECT/CT imaging studies demonstrated significant tumor accumulation at 2 h
post-administration and overall agrees well with the biodistribution data obtained at the
4 h time point.
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2.6

Conclusion
We investigated the steric impact of the DOTA chelator and the length of

hydrocarbon spacers on the biological performance of the [(N-α-Me)Arg8,Dmt11,
Tle12]NT(6-13) pharmacophore. In conclusion, we found that the DOTA does
negatively impact the binding affinity of the studied NTR1-targeted peptide. Optimal
binding affinity could be restored by incorporation of a 4-atom hydrocarbon linker.
Our best candidate (177Lu-N1) demonstrated substantial tumor accumulation, but the
increase in renal retention relative to other literature analogs is likely due to the higher
overall positive charge of the agent.
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Chapter 3:
Investigation of the Biological Impact of Charge
Distribution on a NTR1-Targeted Peptide
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3.1

Abstract
The neurotensin receptor 1 (NTR1) has been shown to be a promising target,

due to its increased level of expression relative to normal tissue, for pancreatic and
colon cancers. This has prompted the development of a variety of NTR1-targeted
radiopharmaceuticals, based on the neurotensin (NT) peptide, for diagnostic and
radiotherapeutic applications. A major obstacle for the clinical translation of
NTR1-targeted radiotherapeutics would likely be nephrotoxicity due to the high levels
of kidney retention. It is well-known that for many peptide-based agents, renal uptake
is influenced by the overall molecular charge. Herein, we investigated the effect of
charge distribution on receptor binding and kidney retention. Using the
[(N-α-Me)Arg8,Dmt11,Tle12]NT(6−13) targeting vector, three peptides (177Lu−K2,
177

Lu−K4, and 177Lu−K6), with the Lys moved closer (K6) or further away (K2) from

the pharmacophore, were synthesized. In vitro competitive binding, internalization
and efflux, and confocal microscopy studies were conducted using the NTR1-positive
HT-29, human colon cancer cell line. The

177/nat

Lu−K6 demonstrated the highest

binding affinity (21.8 ± 1.2 nM) and the highest level of internalization
(4.06% ± 0.20% of the total added amount). In vivo biodistribution, autoradiography,
and metabolic studies of
CF-1 mice.

177

177

Lu−K4 and

Lu-radiolabeled K2, K4, and K6 were examined using

177

Lu−K6 gave the highest levels of in vivo uptake in

NTR1-positive tissues, whereas

177

Lu−K2 yielded nearly 2-fold higher renal uptake

relative to the other radioconjugates. In conclusion, the position of the Lys (positively
charged amino acid) influences the receptor binding, internalization, in vivo
NTR1-targeting efficacy, and kidney retention profile of the radioconjugates. In
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addition, we have found that hydrophobicity likely play a role in the unique
biodistribution profiles of these agents.

3.2

Introduction
The neurotensin receptor 1 (NTR1) is a G-protein coupled receptor that has

been linked to proliferative action in a number of cancers, including colon and
pancreatic cancer [49,125]. In addition, or as a consequence of this proliferative
pathway, NTR1 has also been shown to be overexpressed on the cellular surface of
these cancers. These findings have resulted in significant interest in developing
NTR1-targeted radiopharmaceuticals for diagnostic and therapeutic purposes
[41,43–45,92,96,103,133,143]. To date, NTR1-targeted agents have been largely
based on neurotensin (NT), a thirteen amino acid peptide that has demonstrated
nanomolar binding affinity to the receptor. Researchers have principally focused on
targeting vectors based on the last six (NT(8-13)) or eight (NT(6-13)) amino acids of
the NT sequence. Of the two targeting vectors, the NT(6-13) peptide demonstrates a
marginally higher binding affinity to the NTR1 [144]. One major obstacle that
hampered the development of NTR1-targeted radiopharmaceuticals early on was the
rapid proteolytic degradation of the NT in the serum [32,145]. This situation is
aggravated by the inability of in vitro serum studies to adequately predict in vivo
stability which led to significant underperformance of the NTR1-targeted agents in
preclinical and clinical studies [41,85]. The in vivo instability of these agents has led
to the development of more stable, synthetic derivatives of the NT pharmacophore,
which demonstrate significantly better in vivo performance [43,84,92,143].
The development of receptor-targeted, radiotherapeutic agents based on small
peptide targeting vectors has been an active area of research over the last three decade
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[15,16,19]. However, the translation of these radiotherapeutic peptides, including
NTR1-targeted agents, into the clinic has been, in many cases, hampered by high
renal uptake which can result in dose-limiting toxicities [106,146]. A variety of
reports have investigated both the mechanism and structure-activity relationships
corresponding to the renal uptake and retention of radiolabeled peptides [106,110,116].
From these studies, it has been recognized that the molecular charge is a significant
factor in the renal uptake of radiolabeled peptides, including NTR1-targeted agents
which typically contain two to three positively-charged amino acids (Arg and Lys)
[110,115]. This high renal uptake has been a major hurdle for the potential
development and translation of radiotherapeutic, NTR1-targeted agents.
Our laboratory has

recently begun exploring the development

of

NTR1-targeted agents using a stabilized [(N-α-Me)Arg8,Dmt11,Tle12]NT(6-13)
targeting vector (Lys-Pro-(N-α-Me)Arg-Arg-Pro-Dmt-Tle-Leu) [45]. Although this
pharmacophore exhibits excellent NTR1-positive tumor uptake, it has a total charge
of +2 and exhibits significant renal uptake, reducing its potential for radiotherapeutic
applications. While the molecular charge/renal uptake relationship for NTR1-agents
has been established, we are interested in determining if charge distribution impacts
the receptor avidity and renal uptake and retention of these agents. Herein, we
investigate the biological impact of the translation of the Lys6 relative to the rest of
the pharmacophore. Using a series of NTR1-targeted agents, Figure 3.1, we explore
the structure-activity relationship of these agents using in vitro and in vivo models of
the HT-29 human colon adenocarcinoma cell line.
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3.3

Methods

3.3.1 Materials
Acetonitrile, formic acid, N,N-diisopropylethylamine (DIEA), N,N-dimethylformamide (DMF), dichloromethane (DCM), N,N'-dicyclohexylcarbodiimide (DCC) ,
methyl-t-butyl ether, N-methylpyrrolidone (NMP), bovine serum albumin (BSA),
sodium dodecyl sulfate (SDS), LysoTrackerTM Blue DND-22, CellLight® early
endosome-green fluorescent protein (GFP) and CellLight® late endosome-red
fluorescent protein (RFP) were purchased from Fisher Scientific (Fair Lawn,
NJ).

Fluorenylmethyloxycarbonnyl

(Fmoc)-protected

natural

amino

acids,

Fmoc-(D)leu-OH, Fmoc-Leu-Wang resin (100-200 mesh), and (1-cyano-2-ethoxy-2oxoethylidenaminooxy) dimethylamino-morpholino-carbenium hexafluorophosphate
(COMU)

were

purchased

from

NovaBiochem

(Hoherbrunn,

Germany).

Fmoc-N-Me-Arg(Pbf)-OH was produced by ChemPep, Inc. (Wellington, FL).
Fmoc-2,6-dimethyl-L-tyrosine (Dmt) was from Ontario Chemicals, Inc (Guelph, ON,
Canada). Fmoc-Tle-OH was

purchased from

CreoSalus

(Louisville, KY).

Lutetium-177 chloride (177LuCl3) was obtained from Perkin Elmer (Waltham, MA)
with a specific activity of 32.3 Ci/mg. Naturally abundant lutetium chloride (natLuCl3),
triisopropylsilane and 3,6-dioxa-1,8-octanedithiol were from Sigma-Aldrich (St Louis,
MO). McCoy’s 5A medium (1X; Iwakata & Grace Mod.) with L-glutamine was
obtained from Mediatech, Inc. (Manassas, VA). TrypLETM Express was purchased
from Invitrogen (Grand Island, NY). Penicillin-Streptomycin solution and
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) were from HyClone
Laboratories, Inc (Logan, UT). Heparin was purchased from Elkins-Sinn, Inc (Cherry
Hill, NJ). Fetal Bovine Serum (FBS) was purchased from GibcoTM by Life
Technologies Corporation (Grand Island, NY). BD Cytofix™ Fixation buffer was
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purchased from BD Biosciences (San Jose, CA). The O.C.T compound for tissue
embedding was from Sakura Finetek USA, Inc. (Torrance, CA).
3.3.2 Cell culture
The human colon cancer cell line HT-29 was obtained from American Type
Culture Collection (Manassas, VA) and cultured under vendor-recommended
conditions. Cells were passaged twice weekly in McCoy’s 5A medium supplemented
with 10% FBS, 100 IU/ml penicillin and 100 μg/ml streptomycin at 37 °C in a
humidified incubator containing 5% CO2.
3.3.3 Mouse model
All animal experiments were conducted in accordance with the Principles of
Animal Care outlined by the National Institutes of Health and approved by the
Institutional Animal Care and Use Committee of the University of Nebraska Medical
Center. Eight-week-old CF-1 mice were obtained from Charles River Laboratories
(Wilmington, MA). Animals were housed five per cage in a light- and
temperature-controlled environment. Food and water were given ad libitum.
3.3.4 Solid-phase peptide synthesis (SPPS)
Peptides were synthesized on an automated solid-phase Liberty microwave
peptide synthesizer from CEM (Matthews, NC), employing traditional Fmoc chemistry.
Briefly, the Fmoc-Leu-Wang resin (100 µmol of the resin-substituted peptide anchors)
was deprotected by piperidine, resulting in the formation of a primary amine from
which the C-terminus of the growing peptide was anchored. Fmoc-protected amino
acids (300 µmol) were activated with COMU and sequentially conjugated to the resin.
The resulting peptide was orthogonally deprotected and cleaved from the resin by
shaking in a cocktail consisting of triisopropylsilane (0.125 ml), water (0.125 ml),
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3,6-dioxa-1,8-octanedithiol (0.125 ml), and trifluoroacetic acid (4.625 ml) for 3 h. The
cleaved peptide was subsequently precipitated and washed thrice using cold (0 °C)
methyl-tert-butyl ether (40 ml×3). The crude peptides were dried under vacuum.
3.3.5 Synthesis of Cyanine5-K6 as fluorescent dye
Cyanine5-K6 was synthesized by conjugation of the Cyanine5 (Cy5) carboxylic
acid to the NH2-K6-Wang resin. Briefly, a mixture of Cy5-COOH (6 µmol),
NH2-K6-Wang-resin (6 µmol), COMU (30 µmol) and DIEA (30 µmol) was dissolved
in DMF and shaken overnight at room temperature. After the reaction, the Cy5-K6 was
cleaved from the Wang resin and purified by HPLC.
3.3.6 HPLC purification and analysis methodology
HPLC/MS analyses were performed on a Waters (Milford, MA) e2695 system
equipped with a Waters 2489 absorption detector and a Waters Q-Tof Micro
electrospray ionization mass spectrometer. Sample purification for in vitro studies was
performed on a Phenomenex (Torrance, CA) Jupiter 10 µm Proteo 250 × 4.6 mm C12
column with a flow rate of 1.5 mL/min. For bulk sample purification, a Phenomenex
Jupiter 10 µm Proteo 250 × 10 mm C12 column was used with a flow rate of
5.0 mL/min. HPLC solvents consisted of H2O containing 0.1% formic acid (solvent A)
and acetonitrile containing 0.1% formic acid (solvent B). For unlabeled and
177/nat

Lu-conjugates of K2, K4 and K6, an initial gradient of 85% A: 15% B linearly

decreased to 70% A: 30% B over a 15-minute time period. At the end of the run time for
all HPLC experiments, the column was flushed with the gradient 5% A: 95% B and
re-equilibrated to the starting gradient.
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3.3.7 Labeling with natLuCl3
Naturally abundant Lutetium (natLu) was substituted for 177Lu in the ES-MS and
in vitro binding studies. The conjugate (0.10 mg, 0.06 μmol) was dissolved in
ammonium acetate buffer (0.5 M, 200 μL, pH 5.5) and mixed with a solution of
nat

LuCl3 (1.7mg, 6 μmol). The solution was heated for 45 min at 90 °C. After cooling to

room temperature,
nat

nat

Lu-conjugates were then peak purified by RP-HPLC. All

Lu-conjugates were ≥ 95% pure before mass spectrometric characterization and

in vitro binding studies were performed.
3.3.8 Radiolabeling with 177LuCl3
The conjugate (50 µg, 30 nmol) was dissolved in ammonium acetate buffer
(0.5 M, 100 μL, pH 5.5).

177

LuCl3 (37 MBq, 1 mCi, 0.18 nmol) was added to the vial

containing the conjugate, and the solution was heated for 45 min at 90 °C. To separate
radiolabeled peptides from unlabeled peptides on the HPLC, 4-5 mg of CoCl2 was
added and incubated for 5 min at 90 °C to increase the hydrophobicities of the
unlabeled conjugates [132]. After cooling to room temperature, evaluation and
purification of the radiolabeled conjugates were performed on a Waters 1525 binary
pump equipped with a Waters 2489 absorption detector and a Bioscan (Poway, CA)
Flow Count radiometric detector system. The collected radioconjugate was
concentrated with an Empore (Eagan, MN) C18 high performance extraction disk
followed by elution with ethanol/sterile saline solution (6:4, 400 μL) to provide the
radiolabeled conjugates in high purity. When required, a BSA-saline solution was
added to the radioconjugate to give a solution containing 0.5% BSA.
3.3.9 Distribution coefficient
The distribution coefficient was determined (n = 6, 2 technical (tech) and
3 biological (bio) repeats) for each 177Lu-labeled radioconjugate. In a 1.5 ml centrifuge
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tube, 0.5 mL of 1-octanol was added to 0.5 mL of phosphate-buffered saline (pH 7.4)
containing the radiolabeled peptide (500,000 cpm). The solution was vigorously stirred
for 2 min at room temperature and subsequently centrifuged (8000 x g, 5 min) to yield
two immiscible layers. Aliquots of 100 µL were taken from each layer and the
radioactivity of each was quantified by an LTI (Elburn, IL) Multi-Wiper nuclear
medicine gamma counter.
3.3.10

In vitro competitive binding studies
As described previously [45,132], the half maximal inhibitory concentration

(IC50) for each conjugate was determined (n = 6, 2 tech and 3 bio repeats) for each
177

Lu-labeled radioconjugate using the HT-29 human colon cancer cell line. In these

studies,

177

Lu-N1 (177Lu-DOTA-β-Ala-[(N-α-Me)Arg8,Dmt11,Tle12]NT(6-13)) served

as the competitive radioligand for comparing the relative effectiveness of the unlabeled
and labeled conjugates. HT-29 cells (~1×106) were suspended in 100 µL of McCoy’s
5A medium (pH 7.4, 4.8 mg/mL HEPES, and 2 mg/mL BSA) and incubated at 37 °C
for

45 min in the presence of

177

Lu-N1 (100,000 cpm, 100 µL) and various

concentrations of the unlabeled conjugates and natLu-conjugates (100 µL). At the end of
the incubation, the cells were centrifuged, aspirated and washed with media five times.
The cell-associated radioactivity was measured using a gamma counter and the IC50
values determined by nonlinear regression using the one-binding site model of
GraphPad Prism 5 (La Jolla, CA).
3.3.11

In vitro internalization and efflux studies
The in vitro internalization and efflux studies were performed as stated

previously [45,132]. HT-29 cells (~1×106) were suspended in 100 µL of McCoy’s 5A
medium (pH 7.4, 4.8 mg/mL HEPES, and 2 mg/mL BSA). Cells were incubated at
37°C with each

177

Lu-radioconjugate (100,000 cpm) for up to 2 h. At 15, 30, 60 and
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120 min time points, cells were washed five times with media to remove the unbound
peptide. Surface-bound radioactivity was removed by washing the cells twice with an
acidic buffer (50 mM glycine-HCl/0.1 M NaCl buffer, pH 2.8). The amount of
radioactivity remaining in each cellular pellet was assigned as the internalized fraction.
The cellular uptake of the radioconjugates was presented as a percentage of total
activity added with groups representing internalized and surface-bound radioactivity.
For efflux studies, HT-29 cells (~1×106) were incubated in six-well plates
overnight. On the day of the experiment, HT-29 cells were incubated for 2 h at 37°C in
the presence of 100,000 cpm of each

177

Lu-radioconjugate. Cells were washed

five times with medium (1 ml) to remove the unbound peptide followed by the addition
of fresh medium. At 0, 0.5, 1, 2, 4 and 24 h, the medium for each time point was
harvested for quantitative analysis of ligand efflux. Surface-bound radioactivity was
removed by washing the cells twice with an acidic buffer (50 mM glycine-HCl/0.1 M
NaCl buffer, pH 2.8). The cells were then lysed using a 10 % aqueous SDS solution to
quantify the remaining internalized fractions. The radioactivity in the effluxed,
surface-bound and internalized fractions for each radioconjugate was determined using
a gamma counter. The effluxed fraction is expressed as a percentage of the total
radioactivity in the well, which is the sum of the effluxed, surface-bound and fraction
remaining in the cell.
3.3.12

Confocal microscopy images of the Cy5-K6
HT-29 cells were cultured on a Lab-Tek chambered #1.0 borosilicate

coverglass disk (4 well) overnight at a concentration of 0.05 million cells per well. The
CellLightTM early endosome-GFP and CellLightTM late endosome-RFP reagents were
added to each well and incubated overnight in a humidified atmosphere with 5% CO2 at
37 ºC. After incubation, HT-29 cells were washed with fresh medium and incubated
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with LysoTracker Blue DND-22 for 2 h at a concentration of 1 nM. After again
washing the cells, the Cy5-K6 was diluted in McCoy’s 5A medium and incubated with
HT-29 cells. At 0.5, 2 and 24 h, the unbound Cy5-K6 was washed off. The
formaldehyde fixation buffer was added to the cells and incubated for 10 min. The cells
were washed with PBS and fluorescent images were obtained using an excitation
wavelength of 373 nm (blue), 488 nm (green), 555 nm (red) and 650 nm (Cy5).
Confocal microscopy images were taken on a Leica LSM 510 META Microscope
equipped with an argon laser.
3.3.13

In vivo biodistribution studies
Biodistribution studies were carried out using healthy CF-1 mice. Each mouse

(average weight, 25 g) received an intravenous bolus, via the tail vein, of
177

Lu-radiolabeled K2, K4 or K6 (370 kBq, 10 µCi) in 100 μL of saline. At 1, 4 and 24

h post injection, the mice were sacrificed and the amounts of radioactivity in the tissues
were counted with a NaI (Tl) well detector from AlphaSpectra, Inc. (Grand Junction,
CO). The excised tissues were weighed and results were expressed as percentage of
injected dose per gram of tissue (%ID/g). Blocking studies were carried out by
co-injection with excess unlabeled K6 (250 μg).
3.3.14

Metabolic studies in mice
For metabolic evaluation assays,

177

Lu-K2,

177

Lu-K4 or

177

Lu-K6 (37 MBq,

1mCi) was injected in the tail vein of CF-1 mice. After 10 min, blood was drawn from
the heart of the animals under anesthesia and collected with prechilled polypropylene
tubes, containing heparin, and placed on ice. Blood samples were centrifuged at
2000 g/ 4°C for 10 mins, plasma was collected, mixed with chilled acetonitrile (1:1 v/v
ratio), and centrifuged at 15,000 g/4°C for 10 min. Supernatants were concentrated to a
smaller volume under a gentle N2 gas, diluted with saline, and filtered through a Millex
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GV filter (0.22 μm). After 1 h, urine was collected, filtered with a Millex GV filter
(0.22 μm). All samples were subsequently analyzed by RP-HPLC using the conditions
previously stated.
3.3.15

Autoradiography of the kidney
The kidneys were collected from the metabolic studies, washed with deionized

water, dried and immediately embedded in O.C.T compound on dry ice. Cryostat
sections (10 µm) of tumor sample were exposed to the phosphor plate for 2 days. The
phosphor plate was subsequently scanned by a Typhoon FLA 9500 variable mode
imager (GE Lifesciences) at a 10 µm resolution.
3.3.16

Statistical analysis
Comparisons of groups for in vitro and in vivo studies were analyzed by the

unpaired two-tailed Student’s t test. P values of less than 0.05 were considered
statistically significant.

3.4

Results

3.4.1 Synthesis and radiolabeling
Three NT analogs (Figure 3.1) with linking groups consisting of one lysine (Lys)
and four D-leucine ((D)Leu) in the paradigm DOTA-X-[(N-α-Me)Arg8,Dmt11,Tle12]
NT(7-13), where X= Lys-(D)Leu-(D)Leu-(D)Leu-(D)Leu, K2; (D)Leu-(D)Leu-Lys(D)Leu-(D)Leu, K4; and (D)Leu-(D)Leu-(D)Leu-(D)Leu-Lys, K6, were synthesized by
SPPS. The three analogs, K2, K4 and K6, were named based on the position of Lys in
the peptide sequence. RP-HPLC retention time, mass spectrometric identification and
yields of the unlabeled conjugates and

nat

Lu-conjugates are listed in Table 3.1. The

isolated yields of the conjugates were relatively poor, likely due to the sterics resulting
from conjugation to the secondary amines of the prolines and (N-α-Me)Arg [3]. The

81
purified conjugates were subsequently radiolabeled with

177/nat

LuCl3 (t½ = 6.75 d) by

co-incubation in an ammonium acetate buffer (pH = 5.5) for 45 min at 90 °C. The
radiochemical yields for

177

Lu-K2,

177

Lu-K4, and

177

Lu-K6 were 77.5%, 79.14% and

75.88%, respectively. In addition to the radioconjugates, a Cy5 fluorescent analog of
K6 (Cy5-K6) was synthesized in order to perform cell trafficking studies. Cy5-K6 was
prepared directly from SPPS, Figure 3.2, with an overall isolated yield of 2.5%.
3.4.2 Distribution coefficient
To evaluate the impact of the Lys position on the water solubility of the
radioconjugates, octanol-PBS distribution coefficients at pH 7.4 were measured. The
log Doct/water values for

177

Lu-K2,

177

Lu-K4, and

177

Lu-K6 were -2.53 ± 0.02,

-2.59 ± 0.02 and -2.63 ± 0.01, (P < 0.05), respectively. While, as expected, the
distribution coefficients were similar, the relative hydrophilicities were
177

Lu-K4 >

177

177

Lu-K6 >

Lu-K2, indicating that movement of the Lys closer to pharmacophore

increases hydrophilicity, albeit slightly.
3.4.3 In vitro competitive binding studies
The NTR1 binding affinity of the unlabeled conjugates and

nat

Lu-labeled

conjugates was investigated by competitive binding studies using HT-29 cells. The IC50
values are given in Table 3.1. For the unlabeled conjugates, the IC50 value for K2 was
the highest (P < 0.001) signifying the poorest binding analog investigated. In contrast,
K6 had the lowest IC50 value (P < 0.001) indicating the highest affinity to the NTR1.
For the natLu-labeled K2, K4 and K6, the same trend was found (i.e., binding affinity of
nat

Lu-K6 >

nat

Lu-K4 >

nat

Lu-K2). This reveals that the proximity of the Lys to the

pharmacophore plays a role in increasing the binding strength of the conjugate to the
NTR1.
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Figure 3.1. Structures of the 177Lu-DOTA-X-([(N-α-Me)Arg8,Dmt11,Tle12]NT(7-13)
analogs (Lu-K2, Lu-K4 and Lu-K6) used in this study.
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Figure 3.2. Synthesis of the Cy5-K6 that was utilized in cell trafficking studies.
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Table 3.1. Characterization of K2, K4 and K6.
Analog

Mass

Cal. Mass

([M+2H]+)

Obs. Retention

([M+2H]+)

Yields

Time (min)

IC50 ±
(nM)

K2

962.2

962.5

8.9

5%

48.6 ± 1.2

K4

962.2

962.5

8.8

3%

31.0 ± 1.1

K6

962.2

962.0

8.0

4%

21.8 ± 1.2

nat

1048.2

1048.5

8.8

69%

35.6 ± 1.1

nat

1048.2

1048.6

7.4

76%

23.5 ± 1.1

nat

1048.2

1048.6

7.5

71%

14.8 ± 1.1

Lu-K2
Lu-K4
Lu-K6

SD
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3.4.4 In vitro internalization and efflux studies
The effect of the position of the positive charged amino acid (Lys) on the rates
of internalization (Figure 3.3) and efflux (Figure 3.4) of the radioconjugates was
investigated in HT-29 cells. At time points 15, 30, 60 and 120 min, the cellular uptake
(internalized and surface-bound radioactivity) of the radioconjugates was represented
as a percentage of total activity added. 177Lu-K6 exhibited a statistically higher level of
uptake (P < 0.0001) relative to 177Lu-K2 and 177Lu-K4 at each time point from 15 min
to 120 min. The internalization of

177

Lu-K2 and

177

Lu-K4 was not significantly

different over the initial 60 min time period. However, by 120 min post-incubation, a
statistically significant increase was observed for

177

Lu-K4. At the 120 min

post-incubation time point, the overall uptake for the radioconjugates were

177

Lu-K6

(4.06 ± 0.20%) > 177Lu-K4 (2.64 ± 0.04%) > 177Lu-K2 (1.91 ± 0.09%).
Efflux studies were conducted by incubating the radioconjugates with HT-29
cells for 2 h, washing the cells with media to remove extracellular radioactivity and
monitoring the release of radioactivity from the cells into the extracellular environment.
The effluxed fractions of 177Lu-K2, 177Lu-K4 and 177Lu-K6 were calculated at the 0.5, 1,
2, 4 and 24 h time points. By the 1 h time point, the effluxed fraction for
(15.74 ± 1.13%) was substantially lower than

177

177

Lu-K6

Lu-K2 and 177Lu-K4 (24.78 ± 0.43%

and 25.15 ± 0.93% respectively, P < 0.0001). Statistically lower levels of efflux were
observed for

177

Lu-K6 relative to the other radioconjugates for the remaining time

points. By the 24 h time point,

177

Lu-K6 had effluxed only 20% of the internalized

radioactivity relative to 28% and 31% for 177Lu-K4 and 177Lu-K2, correspondingly.
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Figure 3.3. The uptake of 177Lu-K2, 177Lu-K4 and 177Lu-K6 (internalization and
surface bound) by HT-29 cells. Values are means ± SD (n = 6).
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Figure 3.4. The efflux of the internalized 177Lu-K2, 177Lu-K4 and 177Lu-K6 by HT-29
cells. Values are means ± SD (n = 6).
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3.4.5 Confocal studies of the Cy5-K6
Using HT-29 cells, confocal microscopy images of the Cy5-K6 (pink) were
taken at 0.5, 2 and 24 h, Figure 3.5. Additionally, early endosome (Rab5a, green), late
endosome/lysosome (Rab7a, red) and acidic compartments (LysoTracker™, blue)
were stained and their colocalization with Cy5-K6 quantified, Table 3.2. At 30 min
post-incubation, the Cy5-K6 was shown primarily at the surface of the HT-29 cells with
a small fraction of the Cy5-K6 entering the cell and co-localizing with the early
endosome marker (green). By 2 h post-incubation, Cy5-K6 had distributed into vesicles
that contained all three markers with low to moderate correlation. The Cy5-K6
demonstrated strong correlation/retention in vesicles that were both Rab7a- and
LysoTracker™-positive by the 24 h post-incubation time point.
3.4.6 In vivo biodistribution studies
We investigated the in vivo biodistribution of 177Lu-K2, 177Lu-K4 and 177Lu-K6
at the 1, 4 and 24 h time points (Figure 3.6, 3.7 & 3.8). All three compounds, 177Lu-K2,
177Lu-K4 and

177

Lu-K6, were effectively cleared from the blood after 4 h

post-injection (0.04 ± 0.02 %ID/g, 0.06 ± 0.08 %ID/g and 0.03 ± 0.03 %ID/g,
respectively). At all time points investigated,

177

Lu-K2 and

177

Lu-K6 exhibited

substantially higher levels of liver uptake and retention, relative to 177Lu-K4. At 1 h, the
liver uptake values for

177

Lu-K2 and

177

Lu-K6 were 5.64 ± 0.47 %ID/g and

6.65 ± 0.71 %ID/g, correspondingly. By the 24 h time point, the liver uptake for
177

Lu-K2 and

177

Lu-K6 had dropped modestly to 4.73 ± 0.75 %ID/g and

5.67 ± 0.57 %ID/g, respectively.
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Figure 3.5. Confocal microscopy images of HT-29 cells with GFP-Rab5a, RFP-Rab7a,
LysoTracker and Cy5-K6 at 30 min, 2 h and 24 h.
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Table 3.2. Colocalization of Cy5-K6
Overlap coefficient

2 h (n=4)

24 h (n=6)

0.80 ± 0.12

0.75 ± 0.07

0.73 ± 0.09

Rab7a+ and Cy5-K6+

0

0.56 ± 0.18

0.75 ± 0.13

LysoTracker+and Cy5-K6+

0

0.49 ± 0.14

0.76 ± 0.15

0.51 ± 0.03

0.36 ± 0.11

0.62 ± 0.07

Rab7a+ and LysoTracker+

Rab5a+ and Cy5-K6+

30 min (n=4)
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Additionally,

177

Lu-K6 demonstrated significantly higher lung uptake

(5.08 ± 1.31 %ID/g) at 1 h post-injection relative to the other conjugates
(< 1.11 ± 0.15 %ID/g). The substantial level of uptake in the liver and lung prompted us
to investigate if the biodistribution of the radioconjugates was hindered by aggregate
formation. BSA has been shown to inhibit the aggregation of peptides/proteins in
solution [147,148]. The three radioconjugates were mixed with saline containing
0.5% BSA, to impede any potential aggregation of the radioconjugates. With this in
hand, the 1 h biodistribution experiments were repeated (data presented in the
supporting information) and yielded no substantial changes in organ uptake and overall
distribution profiles.
The kidney uptake of 177Lu-K4 and 177Lu-K6 were statistically lower than that
of

177

Lu-K2 at all time points. At 1 h, the kidney uptake of

127.51 ± 13.14 %ID/g, two fold higher than that of

177

177

Lu-K2 was

Lu-K4 and

177

Lu-K6

(64.8 ± 10.81 %ID/g and 68.98 ± 6.22 %ID/g, respectively). By 24 h post-injection, the
kidney retention of 177Lu-K2 had decreased substantially to 77.75 ± 10.15 %ID/g, but
still significantly higher than

177

Lu-K4 and

177

Lu-K6 (48.75 ± 9.59 %ID/g and

43.96 ± 6.92 %ID/g, correspondingly).
To evaluate the in vivo targeting capabilities of the NTR1-targeted agents, the
uptake of the radioconjugates in the small and large intestines (NTR1-positive tissues)
were evaluated. At the initial 1 h time point,

177

Lu-K4 and

177

Lu-K6 demonstrated a

statistically higher uptake (P < 0.001) in the small intestines (e.g., 4.25 ± 0.75 %ID/g
and 4.46 ± 0.58 %ID/g, correspondingly) relative to 177Lu-K2 (2.72 ± 0.48 %ID/g). By
24 h post-injection, 177Lu-K4 and 177Lu-K6 retained 67.1 and 57.0 % of the 1 h uptake,
while

177

Lu-K2 preserved 66.2 % of the initial uptake. Similar trends of uptake and
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retention for the radioconjugates were observed in the large intestines data. A blocking
study was performed to demonstrate the NTR1-mediated nature of the intestinal uptake.
Using the

177

Lu-K6 as our model radioconjugate, the blocking study at 1 h

demonstrated a substantial reduction of 82.1% and 62.6 % in small and large intestinal
uptake, respectively. Important to note, substantial reduction in uptake due to
NTR1-blocking was not observed in the kidneys or liver, suggesting this uptake is not
NTR1-mediated. However, interestingly, the lung uptake of 177Lu-K6 was shown to be
substantially lower upon NTR1-blocking implying it was NTR1-mediated.
3.4.7 Autoradiography of the kidney
The distribution of radioconjugates/radiometabolites in the kidneys at 10 and
60 min post-injection was investigated using autoradiography, depicted in Figure 3.9.
The autoradiographs of the

177

Lu-K2,

177

Lu-K4 and

177

Lu-K6 show that even in the

early time points, the radioactivity is largely localized in the cortex of the kidney. While
the position of the Lys group does impact the extent of kidney retention, based on the
biodistribution studies, these autoradiographic images demonstrate that it does not
influence residual localization in the kidney.
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Figure 3.6. Biodistribution studies at 1 h p.i. for 177Lu-K2, 177Lu-K4 and 177Lu-K6 in
CF-1 mice. The blocking study was performed with co-administration of
250 µg of K6. The radioactivity uptake of tissues is expressed as a
percentage of injected dose per gram of tissue (%ID/g). Values are
means ± SD (n = 5).
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Figure 3.7. Biodistribution studies at 4 h p.i. for 177Lu-K2, 177Lu-K4 and 177Lu-K6 in
CF-1 mice. The radioactivity uptake of tissues is expressed as %ID/g.
Values are means ± SD (n = 5).
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Figure 3.8. Biodistribution studies at 24 h p.i. for 177Lu-K2, 177Lu-K4 and 177Lu-K6 in
CF-1 mice. The radioactivity uptake of tissues is expressed as %ID/g.
Values are means ± SD (n = 5).

96

Figure 3.9. Autoradiographic images of kidneys sections from CF-1 mice obtained at
10 and 60 min post-administration of 177Lu-K2, 177Lu-K4 and 177Lu-K6.
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3.4.8 Metabolic studies in mice
To evaluate the metabolism of the radioconjugates in vivo, metabolic analyses
were performed on the blood and urine at 10 and 60 min, respectively, Figure 3.10. For
the blood metabolism studies, the recovery efficiencies of the radioactive components
from the samples were ~70 %. At 10 min post-injection, there were substantially higher
levels of radioactivity observed in the blood for
and 14.99, respectively) compared to

177

177

Lu-K2 and

177

Lu-K4 (AUC: 22.56

Lu-K6 (AUC: 2.61). However, the relative

percent of intact radioconjugate was similar, ranging from 70.6 – 74.4 %. Three
primary metabolites were observed in the blood for 177Lu-K2 and 177Lu-K6, while five
were found for

177

Lu-K4. The radiometabolites isolated from the blood had shorter

retention time relative to the intact radioconjugate suggesting an increased
hydrophilicity. Urine analysis at the 1 h time point demonstrated that 43.2 %, 49.8 %
and 34.0 % of the signal corresponded to the intact 177Lu-K2, 177Lu-K4 and 177Lu-K6,
respectively. Three to four major radiometabolites were observed for each
radioconjugate. Correlative identification based on retention times of the
radiometabolites in the blood and urine was somewhat obfuscated due the different
experimental conditions (e.g., sample matrices, analyte concentrations, etc.) leading to
shifts in retention times. However, the major radiometabolite peaks for both the blood
and urine samples had similar retention times and, for the most part, shift patterns
suggesting that many of the radiometabolites were likely chemically identical.

98

Figure 3.10. Metabolism of the 177Lu-K2, 177Lu-K4 and 177Lu-K6. (A) Metabolites of
177
Lu-K2 in the blood at 10 min (upper) and in the urine at 60min (lower);
(B) Metabolites of 177Lu-K4 in the blood at 10 min (upper) and in the urine
at 60 min (lower); (C) Metabolites of 177Lu-K6 in the blood at 10 min
(upper) and in the urine at 60 min (lower).
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3.5

Discussion
To date, NTR1-targeted radiopharmaceuticals have been largely based on two

targeting vector constructs: NT(6-13) and NT(8-13) [43–45,84,103,133,143]. While
the NT(8-13) contains all of the necessary interactions to ensure low nanomolar
binding affinity to the NTR1, the NT(6-13) fragment includes a terminal Lys6 which
has been used by a variety of investigators as a convenient functionalization site for the
incorporation of chelation systems (e.g., DTPA and DOTA) [31,44,84]. Recently, our
laboratory reported a DOTA incorporated [(N-α-Me)Arg8,Dmt11,Tle12]NT(6-13)
analog, based on work from Gruaz-Guyon and co-workers [44], in which the Lys6
remained unfunctionalized (charged) [45]. This analog exhibited significantly higher
uptake in NTR1-positive tissues and kidneys compared to reported analogs that contain
a functionalized (non-charged) Lys6 [44,84]. In order to better understand the role Lys6
plays on tissue uptake, we investigated the impact of positional translation of the Lys,
relative to the pharmacophore, on the biological performance of a series of
NTR1-targeted peptides, 177Lu-K2, 177Lu-K4 and 177Lu-K6, Figure 3.1
Evaluation of the receptor binding affinity of the NTR1-targeted analogs
revealed that the position of the lysine has a modest impact on receptor binding.
Binding affinities were found to decrease correlatively as the lysine is translated away
from the main pharmacophore suggesting that Lys6 has a role in stabilizing the
receptor-ligand complex. Based on what is known concerning NTR1-ligand
interactions [62], we posit that the lysine is able to form weak charge-charge
interactions with the electronegative rim of the binding pocket.
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.Evaluation of the receptor binding affinity of the NTR1-targeted analogs
revealed that the position of the lysine has a modest impact on receptor binding.
Binding affinities were found to decrease correlatively as the lysine is translated away
from the main pharmacophore suggesting that Lys6 has a role in stabilizing the
receptor-ligand complex. Based on what is known concerning NTR1-ligand
interactions [62], we posit that the lysine is able to form weak charge-charge
interactions with the electronegative rim of the binding pocket. The internalization
efficacies of the NTR1-targeted agents were also found to correlatively decrease as the
lysine moved toward the N-terminus of the peptide. This signifies that the

177

Lu-K6,

with Lys6, is more efficient at inducing the internalization of the receptor, possibly due
to enhanced stabilization/residence time of the NTR1-ligand complex. Efflux studies
revealed that both

177

Lu-K2 and

externalization relative to

177

177

Lu-K4 exhibited significantly higher levels of

Lu-K6. However, it is unclear to us how the structure of

the NTR1-targeted agents resulted in this observation.
The cellular trafficking of fluorescently labeled NTR1-targeted agents has been
previously reported by Vandenbulcke, Falciani and co-workers [149,150]. From our
multicolor confocal microscopy studies, the initial uptake (i.e., 30 minute time point) of
the Cy5-K6 demonstrated that internalized fluorescence was taken up, as expected, into
the early endosomal compartments. Interestingly, the rate of Cy5-K6 uptake was much
slower in HT-29 cells than what was observed by Vandenbulcke and co-workers using
NTR1-transfected COS-7 cells [150]. This may be due to a number of factors including
inherent differences in the two cell line phenotypes and levels of NTR1 expression. At
2h post-incubation, the Cy5-K6 demonstrated moderate levels of signal overlap
(0.36 ± 0.11 – 0.56 ± 0.18) with the three compartmental markers. However, by 24 h of
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continuous exposure to Cy5-K6, strong levels of overlap, 0.75 ± 0.13 and 0.76 ± 0.15,
was observed for the Rab7a-positive (red) and Lysotracker™-positive (blue) vesicles,
correspondingly.

Both

Rab7a

and

Lysotracker™

are

markers

for

late

endosomes/lysosomes. Given the 24 h time point, it seems likely that most of the
Cy5-K6 has matriculated to its terminal location in the lysosomes.
Using biodistribution studies in CF-1 mice, the in vivo targeting efficacy of the
NTR1-targeted agents were evaluated. For our NTR1-positive tissue, we utilized the
small and large intestines, which are known to be endogenously expressed in the mouse
[151]. The small intestinal uptake for 177Lu-K4 and 177Lu-K6 were statistically higher
than 177Lu-K2 at all time points with P < 0.01. Similarly, uptake in the large intestines
followed the same trend, but did not meet statistical significance. Blocking studies for
177

Lu-K6 confirmed the NTR1-mediated nature of the uptake in the intestinal tissues.

Given the observed binding affinity trend of

177

Lu-K6 >

177

Lu-K4 >

177

Lu-K2, the

uptake in the intestines suggests other factors than just binding affinity play a role in
determining the in vivo NTR1-targeting efficacy of these agents.
The comparison of

177

Lu-K6 with our previously published analog

177

Lu-N1,

which used the same [(N-α-Me)Arg8,Dmt11,Tle12]NT(6-13) pharmacophore, yielded
interesting disparities [45]. The in vitro binding and internalization characteristics of
177/nat

177

Lu-N1 were similar to

177

Lu-K6. However, the uptake of

177

Lu-K6, as well as

Lu-K2 and 177Lu-K4, in the small and large intestines were roughly two-fold or more

higher than observed for

177

Lu-N1. This increased uptake is likely associated with the

decreased hydrophilicity of this series of agents relative to

177

Lu-N1 (log Doct/water =

-3.15 ± 0.05) leading to enhanced circulation time. Though, it is important to note, this
speculation is based on NTR1-positive intestinal uptake from two different strains of
mice (CF-1 and SCID) which may differ in the level of NTR1-expression.
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All of the NTR1-targeted agents demonstrated significantly (P < 0.0001) higher
kidney uptake (3-6 fold) than observed with the previously reported analog, 177Lu-N1.
This uptake in the kidneys is not NTR1-mediated as demonstrated by our blocking
study. It is well-known that radiolabeled peptides are taken up by the kidney through
active (e.g., megalin and cubulin) and passive (e.g., pinocytosis) means [107,110].
Additionally, the overall charge of the radioconjugate has been shown to influence the
extent of renal uptake [110]. Since the overall charge (+2) of 177Lu-N1 and this series of
NTR1-targeted agents are identical, we attribute this substantial increase in uptake to
increased hydrophobicity of

177

Lu-K2,

177

Lu-K4 and

177

Lu-K6. Currently, it is

unknown which renal uptake mechanism(s) were enhanced as a result of the increased
hydrophobicities of the NTR1-targeted agents.
As demonstrated by autoradiography studies, the retention of the radioactivity
in the kidney occurred in the cortex, which is consistent with literature reports for
neurotensin and other small receptor-targeted peptides [22].

177

Lu-K2 demonstrated

approximately two-fold higher kidney uptake/retention relative to
177

177

Lu-K4 and

Lu-K6. Based on the distribution coefficients, the differences in the hydrophobicity

of the radioconjugates were negligible. Additionally, no substantial differences in the
metabolism of 177Lu-K2 relative to the other radioconjugates were noted. Currently, it
is unclear why the structure of

177

Lu-K2 yields such a significant increase in kidney

uptake. We hypothesize that this dissimilarity is due to unexpected higher renal uptake
by one of the uptake mechanisms for

177

Lu-K2 and/or one of its resulting

radiometabolites.
For both 177Lu-K2 and 177Lu-K6, unexpected retention was observed in the liver
and/or lung. For the DTPA and DOTA containing NTR1-targeted agents reported to
date, significant uptake in these tissues has not been observed [44,45,84,85,103]. Since
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these peptides are significantly more hydrophobic than previously reported analogs,
initial thoughts were that aggregation of the peptides might be contributing to the
uptake in these non-target tissues. Yet, co-formulation with BSA did not substantially
alter the biodistribution profiles of the three radioconjugates. Interestingly, some
reported

99m

Tc-NTR1-targeted agents have been shown to have high liver and lung

uptake [42,92]. Distribution coefficients were not reported for these analogs. However,
based on their structures, we conjecture that hydrophobicity may be a contributing
factor.

3.6

Conclusion
In summary, we investigated the impact of Lys charge distribution on the

biological performance of a series of NTR1-targeted peptides. It was found that
localization of the Lys closer to the pharmacophore lead to modest, but significant,
increases in NTR1 affinity and rates of NTR1-mediated internalization. In vivo
NTR1-targeting was best for radioconjugates (177Lu-K4 and

177

Lu-K6) with the Lys

functionality closest to the targeting vector. The charge distribution of the Lys had an
unexpected and substantial impact on uptake in the liver, lungs and kidneys.
Additionally, the comparison of these findings with the literature suggests that the
hydrophobicity plays a significant role in uptake in both NTR1-positive and
NTR1-negative tissues.
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Chapter 4:
Design and Development of Competitive inhibitors to
protect NTR1-Targeted Peptide from Degradation in vivo.
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4.1

Abstract
The application of radiolabeled NT analogs for detecting and treating

NTR1-positive tumors has been comprised by rapid in vivo degradation. Some of the
enzymes responsible for the degradation of NTR1-targeted analogs are known,
including thimet oligopeptidase (TOP), neutral endopeptidase (NEP) and the
angiotensin 1-converting enzyme (ACE). To investigate if inhibiting these enzymes
can improve the efficacy of NT based analogs, we evaluated the co-administration of
several known inhibitors and competitive substitutes of these enzymes. In vivo
biodistribution studies using HT-29 tumor xenograft mice demonstrated that the
co-administration with enzyme inhibitor, phosphoramidon (PA) significantly increased
the in vivo tumor uptake from 5.55 ± 1.54 %ID/g (control) to 8.39 ± 0.63 %ID/g (with
PA). The other agents tested, including the IPP (ACE inhibitor), bradykinin
(competitive substrates for the peptidases that degraded NT) and peptide fragment of
NT (Pro-Arg-Arg-Pro-Tyr), were not effective at inhibiting in vivo degradation and
increasing NTR1-mediated uptake.

4.2

Introduction
The development of targeted diagnostic and radiotherapeutic agents for cancers

has long been an objective for biomedical sciences [9,16,20,26,30,152,153].
Neurotensin (NT) receptors have been an active area of interest for targeted agent
development due to the overexpression of these receptors on a variety of cancers
[50,51,53,55,57–59,154]. There are currently three known neurotensin receptors
(NTR1, NTR2 and NTR3) [64,67,155]. However, to date, NTR1 has received the most
interest for radiopharmaceutical development due to: 1) the higher NTR1 expression on
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prominent cancers, such as prostate and pancreatic tumors, and 2) the higher affinity of
NTR1 for NT and NT-based analogs [67,156].
NT was discovered over 40 years ago and has since been shown to have
extensive neuromodulatory effects on both the central and peripheral nervous systems
[67,75,79]. This neural hormone is a 13 amino acid peptide (Glu-Leu-Tyr-Glu-AsnLys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu) which exhibits nanomolar affinity for the NTR1
[75,76]. Because of this, NT was the logical starting point for the development of
targeted agents for NTR1-positive cancers. Early work revealed that only the NT(8-13)
fragment was necessary to achieve nanomolar binding affinity [82]. However, it was
also found that the native NT(8-13) sequence was rapidly degraded in vivo, thus
limiting the in vivo targeting efficacy of the agent [87,156]. Investigation into the
enzymes responsible for this degradation implicated several peptidases, including
thimet oligopeptidase (TOP) 3.4.24.15, neutral endopeptidase (NEP) 3.4.24.11 and the
angiotensin-1-converting enzyme (ACE) 2.4.15.1 [87,88,127,157]. Specifically, TOP
has been shown to degrade at the Arg8-Arg9 site; NEP cleaves at the Pro10-Tyr11
position and ACE is capable of degrading the Tyr11-Ile12 amide bond. These finding
have given the impetus for the development of stabilized NTR1-targeted analogs that
employ single or multiple modification with alternative natural and/or non-natural
amino acids to reduce in vivo degradation by these peptidases [31,32,43,44,93]. For
example, our laboratory, have utilized the triply modified [(N-α-Me)Arg8,Dmt11,
Tle12]NT(6-13) targeting vector [45,46]. These modifications have imparted
substantially higher in vivo stability and targeting efficacy relative to the unmodified
NT peptide, but are still relatively quickly degraded in vivo. Another recent approach,
put forth by Nock, de Jong and co-workers, is the administration of enzymatic
inhibitors to increase the in vivo stability of receptor-targeted peptides [97–100]. Using
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analogs of targeted peptides that are in the clinic or under clinical development, these
researchers have demonstrated that phosphoramidon (PA), a known inhibitor of NEP,
could drastically increase the in vivo stability and targeting efficacy of the investigated
agents.
In this study, we explored the use of the enzymatic inhibitor approach in the
context of NTR1-targeted peptides. Specifically, we examined whether the utilization
of inhibitors can decrease the enzymatic degradation and increase the in vivo targeting
efficacy of current “stabilized” NTR1-targeted radioconjugates, such as the
177

Lu-DOTA-β-Ala-[(N-α-Me)Arg8,Dmt11,Tle12]NT(6-13) radioconjugate. As part of

this study, we investigated the enzymatic inhibitors PA (NEP inhibitor) and IPP, a
tripeptide known to inhibit ACE. In addition, we investigated two peptide substrates: 1)
bradykinkin (BK, Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg) a known substrate for both
NEP and ACE [158–160]; and 2) a shortened peptide (SP) fragment (Pro-ArgArg-Pro-Tyr) of NT(6-13) that contains two of the three known cleavage sites. It was
our hypothesis that these sacrificial substrates, which are co-administered at amounts
magnitudes higher than the radioconjugate, would be able to temporarily saturate the
enzyme(s) responsible for the degradation of the NTR1-targeted agents leading to an
increase in in vivo stability. Herein, we report our findings of the in vivo investigation
of the

177

Lu-DOTA-β-Ala-[(N-α-Me)Arg8,Dmt11,Tle12]NT(6-13) radioconjugate,

designated as 177Lu-N1, in conjunction with the above mentioned enzymatic inhibitors.
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4.3

Methods

4.3.1 Materials
Acetonitrile,

formic

N,N-dimethylformamide

acid,

(DMF),

N,N-diisopropylethylamine

dichloromethane

(DCM),

(DIEA),

N,N'-dicyclohexyl-

carbodiimide (DCC) , methyl-t-butyl ether, N-methylpyrrolidone (NMP). Fluorenylmethyloxycarbonnyl (Fmoc)-protected natural amino acids, Fmoc-β-Ala-OH,
Fmoc-Leu-Wang
ethylidenaminooxy)
(COMU)

were

resin

(100-200

mesh),

and

(1-cyano-2-ethoxy-2-oxo-

dimethylamino-morpholino-carbenium
purchased

from

NovaBiochem

hexafluorophosphate

(Hoherbrunn,

Germany).

Fmoc-N-Me-Arg(Pbf)-OH was obtained from ChemPep, Inc. (Wellington, FL).
Fmoc-2,6-dimethyl-L-tyrosine (Dmt) was purchased from Ontario Chemicals, Inc
(Guelph, ON, Canada). Fmoc-Tle-OH was procured from CreoSalus (Louisville, KY).
Lutetium-177 trichloride (177LuCl3) was obtained from Perkin Elmer (Waltham, MA)
with a specific activity of 32.3 Ci/mg. Naturally abundant lutetium trichloride
(natLuCl3), triisopropylsilane and 3,6-dioxa-1,8-octanedithiol were purchased from
Sigma-Aldrich (St Louis, MO). McCoy’s 5A medium (1X; Iwakata & Grace Mod.)
with L-glutamine was obtained from Mediatech, Inc. (Manassas, VA). TrypLETM
Express was procured from Invitrogen (Grand Island, NY). Penicillin-Streptomycin
solution and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) were
obtained from HyClone Laboratories, Inc (Logan, UT). Fetal Bovine Serum (FBS) was
purchased from GibcoTM by Life Technologies Corporation (Grand Island, NY).
Phosphoramidon sodium salt and bradykinin were procured from MP Biomedicals,
LLC (Solon, OH).
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4.3.2 Cell culture
The human colon cancer cell line HT-29 was obtained from American Type
Culture Collection (Manassas, VA) and cultured under vendor-recommended
conditions. Cells were passaged twice weekly in McCoy’s 5A medium supplemented
with 10% FBS, 100 IU/mL penicillin and 100 μg/mL streptomycin at 37 °C in a
humidified incubator containing 5% CO2.
4.3.3 Mouse model
All animal experiments were conducted in accordance with the Principles of
Animal Care outlined by the National Institutes of Health and approved by the
Institutional Animal Care and Use Committee of the University of Nebraska Medical
Center. Eight-week-old CF-1 mice and five-week-old Institute of Cancer Research
severely combined immunodeficient (ICR SCID) mice were obtained from Charles
River Laboratories (Wilmington, MA). Animals were housed five per cage in a lightand temperature-controlled environment. Food and water were given ad libitum. For
xenograft model, bilateral HT-29 tumors were induced by subcutaneous injection of
5.0×106 cells in Matrigel (BD Biosciences). The tumors were allowed to grow for
2-3 weeks reaching a maximal of 1 cm in diameter before the mice were utilized in
pharmacokinetic studies.
4.3.4 Solid-phase peptide synthesis (SPPS)
As published previously, peptides were synthesized on an automated
solid-phase Liberty microwave peptide synthesizer from CEM (Matthews, NC),
employing traditional Fmoc chemistry. Briefly, the Fmoc-Leu-Wang resin (100 µmol
of the resin-substituted peptide anchors) was deprotected by piperidine, resulting in the
formation of a primary amine on the anchored amino acid. Fmoc-protected amino acids
(300 µmol) were activated with COMU and sequentially conjugated to the resin. The
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resulting peptide underwent cleaveage from the resin and orthogonal group
deprotection by shaking in a cocktail consisting of triisopropylsilane (0.125 mL), water
(0.125 mL), 3,6-dioxa-1,8-octanedithiol (0.125 mL), and trifluoroacetic acid (4.625 mL)
for 3 h. The cleaved peptide was subsequently precipitated, filtered and washed thrice
using cold (0 °C) methyl-tert-butyl ether (40 mL×3). The crude peptides were dried
under vacuum.
4.3.5 HPLC purification and analysis methodology
HPLC/MS analyses were performed on a Waters (Milford, MA) e2695 system
equipped with a Waters 2489 absorption detector and a Waters Q-Tof Micro
electrospray ionization mass spectrometer. Sample purification for in vitro studies was
performed on a Phenomenex (Torrance, CA) Jupiter 10 µm Proteo 250 × 4.6 mm C12
column with a flow rate of 1.5 mL/min. For bulk sample purification, a Phenomenex
Jupiter 10 µm Proteo 250 × 10 mm C12 column was used with a flow rate of
5.0 mL/min. HPLC solvents consisted of H2O containing 0.1% formic acid (solvent A)
and acetonitrile containing 0.1% formic acid (solvent B). For unlabeled and
177/nat

Lu-conjugates of N1, an initial gradient of 95% A: 5% B linearly decreased to

85% A: 15% B over a 15-minute time period. For unlabeled SP, an initial gradient of
95% A: 5% B linearly decreased to 90% A: 10% B over a 15-minute time period. For
unlabeled IPP, an initial gradient of 98% A: 2% B linearly decreased to 92% A: 8% B
over a 15-minute time period. At the end of the run time for all HPLC experiments, the
column was flushed with the gradient 5% A: 95% B and re-equilibrated to the starting
gradient.
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4.3.6 Radiolabeling with 177LuCl3
The conjugate (50 µg, 30 nmol) was dissolved in ammonium acetate buffer
(0.5 M, 100 μL, pH 5.5).

177

LuCl3 (37 MBq, 1 mCi, 0.18 nmol) was added to the vial

containing the conjugate, and the solution was heated for 45 min at 90 °C. To separate
radiolabeled peptides from unlabeled peptides on the HPLC, 4-5 mg of CoCl2 was
added and incubated for 5 min at 90 °C to increase the hydrophobicity of the unlabeled
conjugate. After cooling to room temperature, evaluation and purification of the
radiolabeled conjugates were performed on a Waters 1525 binary pump equipped with
a Waters 2489 absorption detector and a Bioscan Flow Count (Poway, CA) radiometric
detector system. The collected radioconjugate was concentrated with an Empore
(Eagan, MN) C18 high performance extraction disk followed by elution with
ethanol/sterile saline solution (6:4, 400 μL) to provide the radiolabeled conjugates in
high purity.
4.3.7 In vitro competitive binding studies
As described previously, the half maximal inhibitory concentration (IC50) for
SP was determined (n = 6, 2 tech and 3 bio repeats) using the HT-29 human colon
cancer cell line. In these studies, 177Lu-N1 (177Lu-DOTA-β-Ala-[(N-α-Me)Arg8,Dmt11,
Tle12]NT(6-13)) served as the competitive radioligand for comparing the relative
effectiveness of the unlabeled conjugates. HT-29 cells (~1×106) were suspended in
100 µL of McCoy’s 5A medium (pH 7.4, 4.8 mg/mL HEPES, and 2 mg/mL BSA) and
incubated at 37 °C for 45 min in the presence of 177Lu-N1 (100,000 cpm, 100 µL) and
various concentrations (from 10-4 M to 10-12 M) of the SP (100 µL). At the end of the
incubation, the cells were centrifuged, aspirated and washed with media five times. The
cell-associated radioactivity was measured using a gamma counter and the IC50 values
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determined by nonlinear regression using the one-binding site model of GraphPad
Prism 5 (La Jolla, CA).
4.3.8 In vivo biodistribution studies on mice
Biodistribution studies were carried out both using healthy CF-1 mice and
xenograft SCID mice. For biodistribution studies on CF-1 mice, each mouse (average
weight, 30 g) received an intravenous bolus, via the tail vein, of 177Lu-radiolabeled N1
(370 kBq, 10 µCi) in 100 μL of saline alone as a control, or with PA (300 µg), IPP
(300 µg), SP (500 µg) or BK (500 µg). For biodistribution studies on xenograft mice,
each mouse (average weight, 25 g) received an intravenous bolus, via the tail vein, of
177

Lu-radiolabeled N1 (370 kBq, 10 µCi) in 100 μL of saline alone as a control, or with

PA (300 µg), or BK (500 µg). At 1 h post injection, the mice were sacrificed and the
amounts of radioactivity in the tissues were counted with a NaI (Tl) well detector from
AlphaSpectra, Inc. (Grand Junction, CO). The excised tissues were weighed and results
were expressed as percentage of injected dose per gram of tissue (%ID/g).
4.3.9 Statistical analysis
Comparisons of groups for in vitro and in vivo studies were analyzed by the
unpaired two-tailed Student’s t test. P values of less than 0.05 were considered
statistically significant.

4.4

Results

4.4.1 Synthesis of the peptides and radiolabeling of N1
The structures of the N1, PA, IPP, BK and SP peptides are depicted in
Figure 4.1. N1, IPP and SP were synthesized by SPPS and purified and characterized by
LC-MS. PA and BK were purchased from commercial sources. Mass spectrometry,
HPLC retention times and overall synthetic yields for the synthesized peptides are
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given in Table 4.1. Yields for N1 were significantly lower than IPP or SP, which can be
attributed to the relative length and increased steric restraints of the N1 peptide [45].
Radiolabeling of N1 with

177

LuCl3 was carried out in an ammonium acetate

buffer (pH 5.5) at 90°C for 45 min. The radioconjugation reaction was examined by
HPLC and found to give > 85% radiochemical yield. The radioconjugate was purified
and characterized by HPLC. The retention time of the radioconjugate (9.8 min) was
consistent with what was previously reported [45].
4.4.2 In vitro competitive binding studies
To confirm NTR1 binding affinity of N1, competitive binding studies were
performed for both N1 and 177Lu-N1 using HT-29 human colorectal cancer cells. The
resulting IC50 value for both compounds were consistent with previous accounts [45].
Since the SP is a fragment of the NT(8-13) targeting vector, the IC50 of this fragment
was evaluated to confirm negligible binding to the NTR1. SP demonstrated no binding
over the concentrations investigated and was found to have an IC50 of > 0.1 mM.
4.4.3 In vivo biodistribution studies using CF-1 mice
The 1 h p.i. biodistribution profiles of 177Lu-N1 in a CF-1 mouse model alone and
co-administered with PA, BK, SP or IPP are shown in Figure 4.2.

177

Lu-N1 cleared

from the blood rapidly with only 0.08 ± 0.01 %ID/g remaining at 1 h. The
co-administration of IPP and SP had no effect on the blood retention of

177

Lu-N1.

However, co-injection with PA and BK did increase the blood retention of the
radioconjugate to 0.17 ± 0.06 %ID/g and 0.29 ± 0.11 %ID/g, respectively. The tissues
that demonstrated the highest degree of uptake of the NTR1-targeted agents is the small
and large intestines and the kidney. Intestinal uptake has been shown to be due to the
expression of NTR1 in the tissue of the mouse [151].
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Figure 4.1. The structures of 177Lu-N1, enzyme inhibitors and competitive substrates.
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Table 4.1. Characteristics of N1, SP and IPP.
Analog

N1

Sequence

DOTA-β-Ala-Lys-Pro-(N-

Mass
Cal.

Mass
Obs.

Retention
Time (min)

Yield

1540.9

1541.9

13.9

11.1%

Me)Arg-Arg-Pro-Dmt-Tle
-Leu-OH
SP

Pro-Arg-Arg-Pro-Tyr

686.4

687.4

7.0

75.5%

IPP

Ile-Pro-Pro

324.2

325.2

6.7

88.9%
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Thus, intestinal uptake, particularly the small intestines, can serve as a positive control
from which to judge the in vivo targeting efficacy of the various formulations. 177Lu-N1
demonstrated a small intestine uptake of 3.21 ± 0.20 %ID/g. Co-administration of the
SP and IPP had either no effect or a slightly negative effect, in the case of IPP, on the
NTR1-mediated uptake of

177

Lu-N1. Conversely, co-formulation with PA and BK

increased small intestine uptake to 4.20 ± 0.34 %ID/g and 5.06 ± 0.54 %ID/g,
correspondingly. While similar, the trend in large intestinal uptake of 177Lu-N1 largely
reflected that of the small-intestines, with exception to the BK co-formulation. The
co-administration of BK yielded a substantial increase in uptake of the radioconjugate
(4.90 ± 0.85 %ID/g).
The observed kidney uptake (13.21 ± 0.36 %ID/g) of

177

Lu-N1 alone reflects

the fact that 177Lu-N1, as with most small peptides, are excreted primarily through the
renal system. It has been demonstrated that this kidney uptake is not NTR1-mediated,
but rather is based on non-specific mechanisms of uptake [45]. Co-injection of SP and
IPP with

177

Lu-N1 had no substantial impact on kidney uptake. However, the

co-administration with PA and BK yielded significantly (P < 0.005) higher levels of
kidney uptake, 20.60 ± 1.93 %ID/g and 16.87 ± 1.94 %ID/g, respectively, compared
to 177Lu-N1.
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Figure 4.2. Biodistribution studies on CF-1 mice at 4 h post-injection. (n=7 for
177
Lu-N1, n=5 for the other group).
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4.4.4 In vivo biodistribution studies on HT-29 human colon cancer xenograft
SCID mice
The 177Lu-N1 formulations with the enzymatic inhibitors were next evaluated in
an HT-29 human colon cancer xenograft mouse model (Figure 4.3). Taking the results
from the CF-1 biodistribution studies into account, only

177

Lu-N1 alone and

formulations with PA and BK were investigated in the xenograft model.
Biodistribution profiles of the SCID model were largely congruent with the data
obtained from the CF-1 mouse model.

177

Lu-N1 uptake in the NTR1-positive, small

intestine was 5.26 ± 1.08 %ID/g. Co-administration of

177

Lu-N1 with PA

(7.04 ± 1.13 %ID/g, P < 0.05) and BK (8.04 ± 1.11 %ID/g, P < 0.01) demonstrated a
corresponding 1.3-fold and 1.5-fold higher radioactivity accumulation compared to
177

Lu-N1 alone. In the large intestine, the 177Lu-N1 co-injection with BK exhibited the

highest uptake (9.34 ± 1.13 %ID/g, P < 0.0001). In contrast, no significant increase in
large intestine uptake was observed for the

177

Lu-N1 co-injection with PA

(2.22 ± 0.29 %ID/g), as compared to 177Lu-N1 alone (2.03 ± 0.55 %ID/g).
Uptake of the

177

Lu-N1 in the NTR1-positive, HT-29 tumors was

5.55 ± 1.54 %ID/g. The tumor uptake increased approximately 1.5-fold for the
co-administered formulation with PA (8.39 ± 0.63 %ID/g). However, the tumor uptake
of

177

Lu-N1 co-injected with BK (3.95 ± 0.57 %ID/g) was not significantly different

with the 177Lu-N1 alone. Interestingly, compared to the CF-1 data, the kidney uptake of
the three groups was not significantly different with uptake values ranging from
23.19 ± 6.97 - 25.65 ± 5.48 %ID/g.
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Figure 4.3. Biodistribution studies on colon cancer xenograft SCID mice at 1 h
post-injection (n=5).
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4.5

Discussion:
During the development of NTR1-targeted peptides, it was quickly realized that

analogs based on the native NT targeting vector were rapidly degraded. This prompted
the development of NT targeting vectors that are resistant to proteolytic degradation to
increase in vivo stability and maintain targeting viability. While this approach has
resulted in more stable and effective imaging and therapeutic agents, degradation of the
structurally modified peptides still occurs and is a determinant to optimal
NTR1-targeting. For example, our laboratory, along with others, have utilized
[(N-α-Me)Arg8,Dmt11,Tle12]NT(6-13) targeting vector and have demonstrated that this
agent is still quickly degraded (e.g., 30% in 10 min) in the blood [46]. The goal of this
study was to investigate if inhibition of the enzymes responsible for the degradation of
NTR1-targeted agents resulted in a significant increase in in vivo targeting. This
premise is based on prior work that demonstrated that receptor-targeted peptides
susceptible to metabolism by NEP demonstrated significantly higher in vivo targeting
when PA, a known NEP inhibitor, was co-administered [97,98,101,161].
The metabolism of NT based analogs has been attributed to several
metallopeptidases, including TOP, neurolysin, NEP and ACE. TOP is a
metalloendopeptidase that is responsible for the degradation of NT at the Arg8-Arg9
position [127,157,162]. Degradation at the Pro10-Tyr11 of NT is attributed to the
metalloendopeptidases neurolysin and NEP [127,157]. Lastly, ACE has been shown to
degrade NT at the Tyr11-Ile12 positions. For the aims of this study, we utilized several
inhibitors of these peptides to evaluate the biological impact on the in vivo efficacy of
NTR1-targeted agents. PA is a potent and relatively selective inhibitor of NEP
(IC50 = 34 nM), but has also shown inhibitor activity for other metalloproteases
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including ACE (IC50 = 78 µM) [163]. IPP is a tripeptide that had demonstrated
inhibitory effects (IC50 = 5 µM) against ACE [164]. BK is a potent vasodilator and a
substrate of ACE and NEP [165,166]. It is envisioned that BK would act as a
“sacrificial” inhibitor, temporarily saturating ACE and NEP, thus temporally reducing
the rate of degradation of NTR1-targeted peptides. Lastly, in the same vein, SP, a
fragment of the NT(8-13) targeting vector, contains two of the three known cleavage
sites. However, due to these proteases being endopeptidases, it is expected that SP
would be a good inhibitor of TOP, but not necessarily neurolysin or NEP.
Our initial investigation into the ability of enzymatic inhibitors to increase the
in vivo targeting efficacy of NTR1-targeted agent was carried out using a CF-1 mouse
model. Utilization of SP and IPP demonstrated no discernable effects with regard to the
biodistribution profile of

177

Lu-N1. Uptake of the radioconjugate into the

NTR1-positive, small and large intestines remained unchanged. This establishes that
the inhibitors, given at relatively high doses, were ineffective at increasing the in vivo
efficacy of the NTR1-targete agent utilized in this study. The reason for this failure may
be due to 177Lu-N1, which uses a modified (i.e., stabilized) targeting vector, no longer
being a good substrate for ACE and TOP. If so, this implies that ACE and TOP are not
the primary enzyme(s) responsible for the in vivo degradation of stabilized,
NTR1-targeted agents. Conversely to this finding, the utilization of PA and BK had a
marked impact on the uptake in the small intestines. Co-administration of

177

Lu-N1

with PA led to a 30.8% increase in radiotracer uptake, while co-formulation with BK
led to a 57.6% increase. BK also had a substantial impact on the uptake in the large
intestines with an increase of 301.6%. Given the selectivity of PA for NEP, it seems
reasonable to conclude that NEP, through proteolytic cleavage, does effect the in vivo
efficacy of stabilized NTR1-targeted agents. This is consistent with what has been
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observed for other neuropeptide-based analogs [97,98,101,102]. Utilization of BK
resulted in the largest increase in NTR1-mediated uptake. However, the interpretation
of the BK impact was obscured, due to its known vasodilation effects. Whether the
increased NTR1-mediated uptake of 177Lu-N1 was due to inhibition of ACE and NEP
and/or its potent vasodilation effect increasing tissue perfusion was unclear.
Taking the results from the CF-1 biodistribution studies into account, we
decided to investigate 177Lu-N1 alone and the co-formulations including PA and BK in
the HT-29 human colon cancer xenograft mouse model. The co-administration of PA
and BK largely gave similar

177

Lu-N1 uptake profiles compared to the CF-1 studies.

One notable difference was the renal uptake. Co-administration of PA or BK did
increased 177Lu-N1 kidney retention in CF-1 mice, but, interestingly, did not lead to a
significant impact on renal uptake in SCID mice. The reason for the divergence in the
renal uptake is unknown, but is possibly due to differences in the mouse strains. For the
formulations investigated, the small and large intestines uptake profiles of the
radiotracer were essentially identical for both mouse models. Using PA, HT-29 tumor
uptake of

177

Lu-N1 increased by 51.2% confirming that PA plays a positive role in

increasing NTR1-mediated uptake through inhibition of NEP. However, the use of BK
demonstrated no increase in HT-29 tumor uptake. BK is able to produce its vasodilation
effect in normal vasculature by indirectly causing the vascular smooth muscle to relax
[167,168]. In contrast, the vasculature of most solid tumors are known to generally lack
smooth muscle [169]. Based on this, our finding strongly suggests that the positive
effect of NTR1-mediated uptake in the intestines is a result of the vasodilation effect of
BK and not on any inhibitory effect.
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4.6

Conclusion
Utilizing inhibitors and competitive substrates for proteases known to degrade

NTR1-targeted agents, we investigated the impact of these agents on the in vivo
receptor-mediated

uptake

and

biodistribution

profile

of

177

Lu-DOTA-

[(N-α-Me)Arg8,Dmt11,Tle12]NT(6-13). At the doses utilized, IPP (ACE inhibitor) and
SP (NT fragment) did not demonstrate a significant effect on NTR1-mediated uptake
or the biodistribution profile of the radioconjugate. Co-injection of the radioconjugate
with BK (ACE and NEP substrate) did demonstrate an increase in uptake in
NTR1-positive tissues, but this increase was determined to be largely due to the
increased perfusion due to the vasodilation effect of BK. However, in vivo studies in
CF-1 and HT-29 tumor xenograft mice did demonstrate a substantial increase
NTR1-mediated uptake in NTR1-positive non-target tissues and tumors. Overall,
these studies demonstrate that PA (NEP and ACE inhibitor) is effective at
enzymatically stabilizing and improving the in vivo efficacy of NTR1-targeted agents.
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Chapter 5:
Conclusions and Future Directions
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NTR1 is overexpressed in several cancers due to its role as a growth pathway
for cancer cells proliferation, invasion and migration [54,56,57,69,138,170,171]. The
native ligand, NT, has been utilized as a base platform for the development of
NTR1-targeted agents for the detection and treatment of receptor positive cancers
[31,43,60,84,92,96]. However, the application of NT-based radiopharmaceuticals has
been comprised by the decreased binding affinity due to the steric hindrance of various
chelators [44,103]. In addition, the unstable nature of NT-based radiopharmaceuticals
has led to a diminished amount of intact peptides that can accumulate at the target sites
(e.g., tumors) [42–44,92,95]. Lastly, NT-based radiopharmaceuticals, as with most
radiopeptides of small size, are primarily excreted via the renal system. As a
consequence, the high kidney uptake of NTR1-targeted agents occurs which is a
concern when considering its application for targeted radiotherapy [15,22]. To shed
further light onto these problems as well as explore approaches that may improve the
clinical

potential

of

NT-based

radiopharmaceuticals,

we

investigated

the

structure-activity relationships of various NTR1-targeted agents. Specifically, we
explored possible strategies to restore binding affinity, determine the effect of charge
distribution on the biological profile of NTR1-targeted agents and evaluate if peptidase
inhibitors were able to increase the in vivo stability of a NTR1-targeted analog.
As demonstrated in the bombesin analogs, the negative effect of macrocyclic
chelator on the binding affinity of receptor-targeted agents could be diminished by the
insertion of spacer groups between the macrocyclic chelator and the binding
sequence [37,172]. To evaluate the effect of inserted spacers on the binding affinity of
NTR1-targeted agents, we synthesized and investigated a stabilized NT-based analog
[(N-α-Me)Arg8,Dmt11,Tle12]NT(6-13)) with various spacers of different length (e.g.,
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null, β-Ala, 5-Ava and 8-Aoc) in Chapter 2. In vitro competitive binding,
internalization and efflux studies were performed on all four NT analogs using HT-29
human colon cancer cells. The in vitro competitive binding assays demonstrated that
the binding affinity was significantly increased compared with the analog without a
spacer. Specifically, the analog with a β-Ala spacer (177Lu-N1) could restore a binding
affinity similar to that of the intact NT. In addition, the

177

Lu-N1 internalized more

rapidly and effluxed more slowly than the other analogs tested, indicating the high
retention of this agent in the HT-29 cells. 177Lu-N1 also exhibited in vitro stability for
24 h in PBS, conditioned medium and human serum. In vivo biodistribution and
SPECT/CT imaging studies of

177

Lu-N1 demonstrated excellent tumor accumulation

(3.1 ± 0.4 %ID/g) in a NTR1-positive colon cancer xenograft model. We concluded
that a spacer of β-Ala or longer could restore the binding affinity of NTR1-targeted
agents containing DOTA. In the future, other spacers with different properties
(e.g., hydrophobicity and charge) could be investigated to determine the effect these
changes have on biological performance.
From the in vivo biodistribution study of

177

Lu-N1, we observed the high

kidney uptake, which could comprise the clinical therapeutic application of this agent.
The high, non-specific kidney uptake is a common hurdle for the development of
peptide-based radiopharmaceuticals. Based on numerous investigations concerning the
mechanism and cause of peptide uptake in the kidneys, the charge of the NT-based
radiopharmaceuticals has been shown to play an important role in the renal uptake.
However, the effect of charge distribution of the NT-based radiopharmaceuticals on the
biological profile, including the binding affinity and retention in non-target tissues
(e.g., kidneys), has not been investigated. To investigate the influence of charge
distribution on NTR1-targeted agents, we synthesized three analogs with the spacers
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composed of Lys and D-Leu in Chapter 3. These analogs had the same net charge, but
with different charge distributions through the sequence (K2, K4 and K6). The effect of
the charge distribution was evaluated on the NTR1 binding, receptor-mediated uptake
and in vivo biodistribution. With the movement of Lys towards the binding sequence,
the binding affinity increased. The in vivo biodistribution of the non-target organs and
receptor-positive organs showed different uptake patterns, indicating the influence of
the charge distribution of the peptide. The noticeable uptake in the lung and liver of
177

Lu-K2, K4 and K6 was most likely due to the hydrophobicity of these agents. The in

vivo radiometabolites generated by the

177

Lu-K2, K4 and K6 were also investigated.

These studies demonstrated that even these “stabilized” NTR1-targeted agents undergo
degradation in vivo. However, further studies to determine the chemical identity of the
radiometabolites generated, including the molecular weight and sequence, have yet to
be performed. With such information, the design of improved NT-based
radiopharmaceuticals with higher in vivo stability will be possible.
In the last study, we investigated the effect of selective inhibitors and
competitive substrates for the enzymes responsible for the degradation of the NT-based
radiopharmaceutical in Chapter 4. Using 177Lu-N1, the co-administration of PA (a NEP
inhibitor) was found to increase NTR1-positive, tumor uptake 1.6 fold in colon cancer
xenograft mice. However, with the co-administration of the other inhibitor, IPP (an
ACE inhibitor), and competitive substrates (SP and BK), no increase in the
receptor-mediated

uptake

was

observed.

The

promising

result

from

the

co-administration of PA will encourage future studies to optimize the use of PA as well
as the investigation of other inhibitors to improve the in vivo stability and potential of
NTR1-targeted agents.
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With the studies performed herein, we evaluated the structure-activity
relationships of NTR1-targeted agents as well as explored approaches that could
ultimately increase translational potential. It is expected that the strategies and insights
found in this work will inspire the design of the next generation of NTR1-targeted
agents. Ultimately, it is hoped that, with these new and improved analogs, the
successful translation of NTR1-targeted agents into the clinic will be achieved.
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